<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><?covid-19-tdm ?><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">63502</article-id><article-id pub-id-type="doi">10.7554/eLife.63502</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Short Report</subject></subj-group><subj-group subj-group-type="heading"><subject>Computational and Systems Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group></article-categories><title-group><article-title>Longitudinal high-throughput TCR repertoire profiling reveals the dynamics of T-cell memory formation after mild COVID-19 infection</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-100050"><name><surname>Minervina</surname><given-names>Anastasia A</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9884-6351</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-62208"><name><surname>Komech</surname><given-names>Ekaterina A</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-194072"><name><surname>Titov</surname><given-names>Aleksei</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-194070"><name><surname>Bensouda Koraichi</surname><given-names>Meriem</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-166279"><name><surname>Rosati</surname><given-names>Elisa</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-2635-6422</contrib-id><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-209967"><name><surname>Mamedov</surname><given-names>Ilgar Z</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-166280"><name><surname>Franke</surname><given-names>Andre</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-194071"><name><surname>Efimov</surname><given-names>Grigory A</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-209966"><name><surname>Chudakov</surname><given-names>Dmitriy M</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-0430-790X</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="other" rid="fund7"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-195822"><name><surname>Mora</surname><given-names>Thierry</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-5456-9361</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-50904"><name><surname>Walczak</surname><given-names>Aleksandra M</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-2686-5702</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-122730"><name><surname>Lebedev</surname><given-names>Yuri B</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4554-4733</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-62204"><name><surname>Pogorelyy</surname><given-names>Mikhail V</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0773-1204</contrib-id><email>m.pogorely@gmail.com</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry</institution><addr-line><named-content content-type="city">Moscow</named-content></addr-line><country>Russian Federation</country></aff><aff id="aff2"><label>2</label><institution>Pirogov Russian National Research Medical University</institution><addr-line><named-content content-type="city">Moscow</named-content></addr-line><country>Russian Federation</country></aff><aff id="aff3"><label>3</label><institution>National Research Center for Hematology</institution><addr-line><named-content content-type="city">Moscow</named-content></addr-line><country>Russian Federation</country></aff><aff id="aff4"><label>4</label><institution>Laboratoire de physique de l'École Normale Supérieure, ENS, PSL, Sorbonne Universite, Universite de Paris, and CNRS</institution><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff><aff id="aff5"><label>5</label><institution>Institute of Clinical Molecular Biology, Kiel University</institution><addr-line><named-content content-type="city">Kiel</named-content></addr-line><country>Germany</country></aff><aff id="aff6"><label>6</label><institution>Masaryk University, Central European Institute of Technology</institution><addr-line><named-content content-type="city">Brno</named-content></addr-line><country>Czech Republic</country></aff><aff id="aff7"><label>7</label><institution>V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology</institution><addr-line><named-content content-type="city">Moscow</named-content></addr-line><country>Russian Federation</country></aff><aff id="aff8"><label>8</label><institution>Moscow State University</institution><addr-line><named-content content-type="city">Moscow</named-content></addr-line><country>Russian Federation</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Krishna</surname><given-names>Sandeep</given-names></name><role>Reviewing Editor</role><aff><institution>National Centre for Biological Sciences‐Tata Institute of Fundamental Research</institution><country>India</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Davenport</surname><given-names>Miles P</given-names></name><role>Senior Editor</role><aff><institution>University of New South Wales</institution><country>Australia</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>05</day><month>01</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>10</volume><elocation-id>e63502</elocation-id><history><date date-type="received" iso-8601-date="2020-09-27"><day>27</day><month>09</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2021-01-05"><day>05</day><month>01</month><year>2021</year></date></history><permissions><copyright-statement>© 2021, Minervina et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Minervina et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-63502-v2.pdf"/><abstract><p>COVID-19 is a global pandemic caused by the SARS-CoV-2 coronavirus. T cells play a key role in the adaptive antiviral immune response by killing infected cells and facilitating the selection of virus-specific antibodies. However, neither the dynamics and cross-reactivity of the SARS-CoV-2-specific T-cell response nor the diversity of resulting immune memory is well understood. In this study, we use longitudinal high-throughput T-cell receptor (TCR) sequencing to track changes in the T-cell repertoire following two mild cases of COVID-19. In both donors, we identified CD4<sup>+</sup> and CD8<sup>+</sup> T-cell clones with transient clonal expansion after infection. We describe characteristic motifs in TCR sequences of COVID-19-reactive clones and show preferential occurrence of these motifs in publicly available large dataset of repertoires from COVID-19 patients. We show that in both donors, the majority of infection-reactive clonotypes acquire memory phenotypes. Certain T-cell clones were detected in the memory fraction at the pre-infection time point, suggesting participation of pre-existing cross-reactive memory T cells in the immune response to SARS-CoV-2.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>COVID-19</kwd><kwd>TCR</kwd><kwd>RepSeq</kwd><kwd>SARS-CoV-2</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100006769</institution-id><institution>Russian Science Foundation</institution></institution-wrap></funding-source><award-id>RSF 20-15-00351</award-id><principal-award-recipient><name><surname>Lebedev</surname><given-names>Yuri B</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001659</institution-id><institution>Deutsche Forschungsgemeinschaft</institution></institution-wrap></funding-source><award-id>Exc2167</award-id><principal-award-recipient><name><surname>Franke</surname><given-names>Andre</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001659</institution-id><institution>Deutsche Forschungsgemeinschaft</institution></institution-wrap></funding-source><award-id>4096610003</award-id><principal-award-recipient><name><surname>Franke</surname><given-names>Andre</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100010663</institution-id><institution>H2020 European Research Council</institution></institution-wrap></funding-source><award-id>COG 724208</award-id><principal-award-recipient><name><surname>Walczak</surname><given-names>Aleksandra M</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002261</institution-id><institution>Russian Foundation for Basic Research</institution></institution-wrap></funding-source><award-id>19-54-12-011</award-id><principal-award-recipient><name><surname>Mamedov</surname><given-names>Ilgar Z</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002261</institution-id><institution>Russian Foundation for Basic Research</institution></institution-wrap></funding-source><award-id>18-19-09132</award-id><principal-award-recipient><name><surname>Mamedov</surname><given-names>Ilgar Z</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004569</institution-id><institution>Ministry of Science and Higher Education</institution></institution-wrap></funding-source><award-id>075-15-2019-1789</award-id><principal-award-recipient><name><surname>Chudakov</surname><given-names>Dmitriy M</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Longitudinal tracking of individual T-cell clones reveals the expansion of pre-existing T-cell memory in response to SARS-CoV-2 infection.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>COVID-19 is a global pandemic caused by the novel SARS-CoV-2 betacoronavirus (<xref ref-type="bibr" rid="bib40">Vabret et al., 2020</xref>). T cells are crucial for clearing respiratory viral infections and providing long-term immune memory (<xref ref-type="bibr" rid="bib31">Schmidt and Varga, 2018</xref>; <xref ref-type="bibr" rid="bib38">Swain et al., 2012</xref>). Two major subsets of T cells participate in the immune response to viral infection in different ways: activated CD8<sup>+</sup> T cells directly kill infected cells, while subpopulations of CD4<sup>+</sup> T cells produce signalling molecules that regulate myeloid cell behaviour, drive, and support CD8 response and the formation of long-term CD8 memory, and participate in the selection and affinity maturation of antigen-specific B cells, ultimately leading to the generation of neutralizing antibodies. In SARS-1 survivors, antigen-specific memory T cells were detected up to 11 years after the initial infection, when viral-specific antibodies were undetectable (<xref ref-type="bibr" rid="bib20">Ng et al., 2016</xref>; <xref ref-type="bibr" rid="bib22">Oh et al., 2011</xref>). The T-cell response was shown to be critical for protection in SARS-1-infected mice (<xref ref-type="bibr" rid="bib42">Zhao et al., 2010</xref>). Patients with X-linked agammaglobulinemia, a genetic disorder associated with lack of B cells, have been reported to recover from symptomatic COVID-19 (<xref ref-type="bibr" rid="bib29">Quinti et al., 2020</xref>; <xref ref-type="bibr" rid="bib36">Soresina et al., 2020</xref>), suggesting that in some cases, T cells are sufficient for viral clearance. Thevarajan et al. showed that activated CD8<sup>+</sup>HLA<sup>–</sup>DR<sup>+</sup>CD38<sup>+</sup> T cells in a mild case of COVID-19 significantly expand following symptom onset, reaching their peak frequency of 12% of CD8<sup>+</sup> T cells on day 9 after symptom onset, and contract thereafter (<xref ref-type="bibr" rid="bib39">Thevarajan et al., 2020</xref>). Given the average time of 5 days from infection to the onset of symptoms (<xref ref-type="bibr" rid="bib3">Bi et al., 2020</xref>), the dynamics and magnitude of T-cell response to SARS-CoV-2 is similar to that observed after immunization with live vaccines (<xref ref-type="bibr" rid="bib18">Miller et al., 2008</xref>). SARS-CoV-2-specific T cells were detected in COVID-19 survivors by activation following stimulation with SARS-CoV-2 proteins (<xref ref-type="bibr" rid="bib21">Ni et al., 2020</xref>) or by viral protein-derived peptide pools (<xref ref-type="bibr" rid="bib41">Weiskopf et al., 2020</xref>; <xref ref-type="bibr" rid="bib5">Braun et al., 2020</xref>; <xref ref-type="bibr" rid="bib35">Snyder et al., 2020</xref>; <xref ref-type="bibr" rid="bib14">Le Bert et al., 2020</xref>; <xref ref-type="bibr" rid="bib17">Meckiff et al., 2020</xref>; <xref ref-type="bibr" rid="bib1">Bacher et al., 2020</xref>; <xref ref-type="bibr" rid="bib24">Peng et al., 2020</xref>). Some of the T cells activated by peptide stimulation were shown to have a memory phenotype (<xref ref-type="bibr" rid="bib41">Weiskopf et al., 2020</xref>; <xref ref-type="bibr" rid="bib14">Le Bert et al., 2020</xref>; <xref ref-type="bibr" rid="bib16">Mateus et al., 2020</xref>), and some potentially cross-reactive CD4<sup>+</sup> T cells were found in healthy donors (<xref ref-type="bibr" rid="bib5">Braun et al., 2020</xref>; <xref ref-type="bibr" rid="bib12">Grifoni et al., 2020</xref>; <xref ref-type="bibr" rid="bib32">Sekine et al., 2020</xref>; <xref ref-type="bibr" rid="bib1">Bacher et al., 2020</xref>).</p><p>T cells recognise short pathogen-derived peptides presented on the cell surface of the major histocompatibility complex (MHC) using hypervariable T-cell receptors (TCR). TCR repertoire sequencing allows for the quantitative tracking of T-cell clones in time, as they go through the expansion and contraction phases of the response. It was previously shown that quantitative longitudinal TCR sequencing is able to identify antigen-specific expanding and contracting T cells in response to yellow fever vaccination with high sensitivity and specificity (<xref ref-type="bibr" rid="bib19">Minervina et al., 2020</xref>; <xref ref-type="bibr" rid="bib26">Pogorelyy et al., 2018</xref>; <xref ref-type="bibr" rid="bib7">DeWitt et al., 2015</xref>). Not only clonal expansion but also significant contraction from the peak of the response are distinctive traits of T-cell clones specific to the virus (<xref ref-type="bibr" rid="bib26">Pogorelyy et al., 2018</xref>).</p><p>In this study, we use longitudinal TCRalpha and TCRbeta repertoire sequencing to quantitatively track T-cell clones that significantly expand and contract after recovery from a mild COVID-19 infection, and determine their phenotype. We reveal the dynamics and the phenotype of the memory cells formed after infection, identify pre-existing T-cell memory clones participating in the response, and describe public TCR sequence motifs of SARS-CoV-2-reactive clones, suggesting a response to immunodominant epitopes.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Longitudinal tracking of TCR repertoires of COVID-19 patients</title><p>In the middle of March (day 0), donor W female and donor M male (both healthy young adults) returned to their home country from the one of the centres of the COVID-19 outbreak in Europe at the time. Upon arrival, according to local regulations, they were put into strict self-quarantine for 14 days. On day 3 of self-isolation, both developed low-grade fever, fatigue, and myalgia, which lasted 4 days and was followed by a temporary loss of smell for donor M. On days 15, 30, 37, 45, and 85, we collected peripheral blood samples from both donors (<xref ref-type="fig" rid="fig1">Figure 1a</xref>). The presence of IgG and IgM SARS-CoV-2-specific antibodies in the plasma was measured at all time points using SARS-CoV-2 S-RBD domain-specific ELISA (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). From each blood sample, we isolated peripheral blood mononuclear cells (PBMCs, in two biological replicates), CD4<sup>+</sup>, and CD8<sup>+</sup> T cells. Additionally, on days 30, 45, and 85, we isolated four T-cell memory subpopulations (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2a</xref>): effector memory (EM: CCR7<sup>−</sup>CD45RA<sup>−</sup>), effector memory with CD45RA re-expression (EMRA: CCR7<sup>−</sup>CD45RA<sup>+</sup>), central memory (CM: CCR7<sup>+</sup>CD45RA<sup>−</sup>), and stem cell-like memory (SCM: CCR7<sup>+</sup>CD45RA<sup>+</sup>CD95<sup>+</sup>). From all samples, we isolated RNA and performed TCRalpha and TCRbeta repertoire sequencing as previously described (<xref ref-type="bibr" rid="bib25">Pogorelyy et al., 2017</xref>). For both donors, TCRalpha and TCRbeta repertoires were obtained for other projects 1 and 2 years prior to infection. Additionally, TCR repertoires of multiple samples for donor M – including sorted memory subpopulations – are available from a published longitudinal TCR sequencing study after yellow fever vaccination (donor M1 samples in <xref ref-type="bibr" rid="bib19">Minervina et al., 2020</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Longitudinal tracking of T-cell clones after mild COVID-19.</title><p>(<bold>a</bold>) Study design. Peripheral blood of two donors was sampled longitudinally on days 15, 30, 37, 45, and 85 after arrival in Russia. At each time point, we evaluated SARS-CoV-2-specific antibodies using ELISA (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>) and isolated PBMCs in two biological replicates. Additionally, CD4<sup>+</sup> and CD8<sup>+</sup> cells were isolated from a separate portion of blood, and EM, CM, EMRA, and SCM memory subpopulations were FACS sorted on days 30, 45, and 85. For each sample, we sequenced TCRalpha and TCRbeta repertoires. For both donors, pre-infection PBMC repertoires were sampled in 2018 and 2019 for other projects. (<bold>b, c</bold>) PCA of clonal temporal trajectories identifies three groups of clones with distinctive behaviours. Left: First two principal components of the 1000 most abundant TCRbeta clonotype frequencies normalized by maximum value for each clonotype in PBMC at post-infection time points. Colour indicates hierarchical clustering results of principal components; symbol indicates if clonotype was called as significantly contracted from day 15 to day 85 (triangles) or expanded from day 15 to day 37 (circles) by both edgeR and NoisET (<xref ref-type="fig" rid="fig1s5">Figure 1—figure supplement 5</xref> shows overlap between clonal trajectory clusters and edgeR/NoisET hits). Right: Each curve shows the average ±2.96 SE of normalized clonal frequencies from each cluster. Contracting (<bold>d</bold>) and expanding (<bold>e</bold>) clones include both CD4<sup>+</sup> and CD8<sup>+</sup> T cells and are less abundant in pre-infection repertoires. T-cell clones significantly contracted from day 15 to day 85 (<bold>d</bold>) and significantly expanded from day 15 to day 37 (<bold>e</bold>) were identified in both donors. The fraction of contracting (<bold>d</bold>) and expanding (<bold>e</bold>) TCRbeta clonotypes in the total repertoire (calculated as the sum of frequencies of these clonotypes in the second PBMC replicate at a given time point and corresponding to the fraction of responding cells of all T cells) is plotted in log-scale for all reactive clones (left) and reactive clones with the CD4 (middle) and CD8 (right) phenotypes. Similar dynamics were observed in TCRalpha repertoires (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref>) and for significantly expanded/contracted clones identified with the NoisET Bayesian differential expansion statistical model alone (<xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4</xref>).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63502-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Both donors developed anti-SARS-CoV-2 IgG and IgM responses by day 15 post-infection.</title><p>(<bold>a</bold>) The relative level of SARS-CoV-2 S-RBD domain-specific IgG (y-axis) is plotted against time. Solid black line shows the threshold for positive testing. (<bold>b</bold>) Relative IgM levels in donors M and W are shown over time. Relative IgM levels for pre-pandemic serum samples from healthy donors are shown on the left (green dots).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63502-fig1-figsupp1-v2.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Gating strategy for T cell subsets.</title><p>(<bold>a</bold>) Memory subpopulation gating strategy. Three populations of memory T cells: EM, CM, and EMRA are defined by CCR7 and CD45RA markers; SCM are distinguished from naive CCR7<sup>+</sup> CD45RA<sup>+</sup> T cells by CD95 expression. (<bold>b</bold>) HLA-A*02:01-YLQPRTFLL subpopulation gating strategy. On day 25 post-infection, donor M participated in study by <xref ref-type="bibr" rid="bib33">Shomuradova et al., 2020</xref> (as donor p1434), where his T cells were in vitro expanded and stained with HLA-A*02:01-YLQPRTFLL tetramer, TCRalpha, and TCRbeta repertoires were sequenced and resulting sequences deposited to VDJdb. See <xref ref-type="bibr" rid="bib33">Shomuradova et al., 2020</xref> for experimental details.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63502-fig1-figsupp2-v2.tif"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 3.</label><caption><title>Longitudinal tracking of T-cell clones after mild COVID-19 with TCRalpha repertoire sequencing.</title><p>(<bold>a, b</bold>) PCA of clonal temporal trajectories identifies three groups of clones with distinctive behaviours. Left: First two principal components of the 1000 most abundant TCRalpha clonotype frequencies normalized by maximum value for each clonotype in PBMC at post-infection time points. Colour indicates hierarchical clustering results of principal components; symbol indicates if clonotype was called as significantly contracted from day 15 to day 85 (triangles) or expanded from day 15 to day 37 (circles) by both edgeR and NoisET (<xref ref-type="fig" rid="fig1s5">Figure 1—figure supplement 5</xref> shows overlap between clonal trajectory clusters and edgeR/NoisET hits). Right: Each curve shows the average ±2.96 SE of normalized clonal frequencies from each cluster. Contracting (<bold>c</bold>) and expanding (<bold>d</bold>) clones include both CD4<sup>+</sup> and CD8<sup>+</sup> T cells and are less abundant in pre-infection repertoires. T-cell clones significantly contracted from day 15 to day 85 (<bold>c</bold>) and significantly expanded from day 15 to day 37 (<bold>d</bold>) were identified in both donors. The fraction of contracting (<bold>c</bold>) and expanding (<bold>d</bold>) TCRalpha clonotypes in the total repertoire (calculated as the sum of frequencies of these clonotypes in the second PBMC replicate at a given time point and corresponding to the fraction of responding cells of all T cells) is plotted in log-scale for all reactive clones (left) and reactive clones with the CD4 (middle) and CD8 (right) phenotypes.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63502-fig1-figsupp3-v2.tif"/></fig><fig id="fig1s4" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 4.</label><caption><title>Comparison of edgeR and NoisET clonal expansion detection procedures.</title><p>The fraction (plotted in the log-scale) of contracting (<bold>a</bold>) and expanding (<bold>d</bold>) TCRbeta clonotypes in the total repertoire was estimated using subsets of expanded and contracted clones called by edgeR (green) and NoisET (purple) models. Overlaps for contracted clones (<bold>b, c</bold>) and expanded clones (<bold>e, f</bold>) identified by both models are shown on the right.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63502-fig1-figsupp4-v2.tif"/></fig><fig id="fig1s5" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 5.</label><caption><title>The overlap between clusters of clonal trajectories identified by PCA and groups of expanding/contracting clones identified with edgeR/NoisET.</title><p>For each cluster of clonal trajectories identified on <xref ref-type="fig" rid="fig1">Figure 1b,c</xref>, <xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3a,b</xref>, we show overlap with groups of significantly (called by edgeR and NoisET simultaneously) expanding clonotypes from day 15 to day 37 in yellow, significantly contracting clonotypes from day 15 to day 85 in green, other clonotypes are shown in purple (‘stable’ clonotypes that were not called significant by edgeR and NoisET simultaneously). Bar heights show fraction of abundant clonotypes in PCA cluster overlapping with expanding/contracting/non-significant groups called by edgeR/NoisET; raw number of overlapping clonotypes is shown inside bars.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63502-fig1-figsupp5-v2.tif"/></fig></fig-group></sec><sec id="s2-2"><title>Two waves of T-cell clone response</title><p>From previously described activated T-cell dynamics for SARS-CoV-2 (<xref ref-type="bibr" rid="bib39">Thevarajan et al., 2020</xref>), and immunization with live vaccines (<xref ref-type="bibr" rid="bib18">Miller et al., 2008</xref>), the peak of the T-cell expansion is expected around day 15 post-infection, and responding T cells significantly contract afterwards. However, <xref ref-type="bibr" rid="bib41">Weiskopf et al., 2020</xref> reports an increase of SARS-CoV-2-reactive T cells at later time points, peaking in some donors after 30 days following symptom onset. To identify groups of T-cell clones with similar dynamics in an unbiased way, we used principal component analysis (PCA) in the space of T-cell clonal trajectories (<xref ref-type="fig" rid="fig1">Figure 1b,c</xref>). This exploratory data analysis method allows us to visualize major trends in the dynamics of abundant TCR clonotypes (occurring within top 1000 on any post-infection time points) between multiple time points.</p><p>In both donors, and in both TCRalpha and TCRbeta repertoires, we identified three clusters of clones with distinct dynamics. The first cluster (<xref ref-type="fig" rid="fig1">Figure 1b,c</xref>, purple) corresponded to abundant TCR clonotypes that had constant concentrations across time points, the second cluster (<xref ref-type="fig" rid="fig1">Figure 1b,c</xref>, green) showed contraction dynamics from day 15 to day 85, and the third cluster (<xref ref-type="fig" rid="fig1">Figure 1b,c</xref>, yellow) showed an unexpected clonal expansion from day 15 with a peak on day 37 followed by contraction. The clustering and dynamics are similar in both donors and are reproduced in TCRbeta (<xref ref-type="fig" rid="fig1">Figure 1b,c</xref>) and TCRalpha (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3a,b</xref>) repertoires. We next used edgeR, a software for differential gene expression analysis (<xref ref-type="bibr" rid="bib30">Robinson et al., 2010</xref>) and NoisET, a Bayesian differential expansion model (<xref ref-type="bibr" rid="bib28">Puelma Touzel et al., 2020</xref>), to specifically detect changes in clonotype concentration between pairs of time points in a statistically reliable way and without limiting the analysis to the most abundant clonotypes. Both NoisET and edgeR use biological replicate samples collected at each time point to train a noise model for sequence counts. Results for the two models were similar (<xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4</xref>), and we conservatively defined as expanded or contracted the clonotypes that were called by both models simultaneously. We identified 291 TCRalpha and 295 TCRbeta clonotypes in donor W and 607 TCRalpha and 616 TCRbeta in donor M significantly contracted from day 15 to day 85 (largely overlapping with cluster 2 of clonal trajectories, <xref ref-type="fig" rid="fig1s5">Figure 1—figure supplement 5</xref>). One hundred and seventy six TCRalpha and 278 TCRbeta for donor W and 293 TCRalpha and 427 TCRbeta clonotypes for donor M were significantly expanded from days 15 to 37 (corresponding to cluster 3 of clonal trajectories).</p><p>Note that, to identify putatively SARS-CoV-2-reactive clones, we only used post-infection time points, so that our analysis can be reproduced in other patients and studies where pre-infection time points are unavailable. However, tracking the identified responding clones back to pre-infection time points reveals strong clonal expansions from pre- to post-infection (<xref ref-type="fig" rid="fig1">Figure 1d,e</xref>, <xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3c,d</xref>). For brevity, we further refer to clonotypes significantly contracted from day 15 to 85 as <italic>contracting</italic> clones and clonotypes significantly expanding from day 15 to 37 as <italic>expanding</italic> clones. Contracting clones corresponded to 2.5% and 0.9% of T cells on day 15 post-infection, expanding clones reached 1.1% and 0.8% on day 37 for donors M and W, respectively (<xref ref-type="fig" rid="fig1">Figure 1d,e</xref>, left). This magnitude of the T-cell response is of the same order of magnitude as previously observed after live yellow fever vaccine immunization of donor M (6.7% T cells on day 15 post-vaccination). For each contracting and expanding clone, we determined their CD4/CD8 phenotype using separately sequenced repertoires of CD4<sup>+</sup> and CD8<sup>+</sup> subpopulations (see Materials and methods). Both CD4<sup>+</sup> and CD8<sup>+</sup> subsets participated actively in the response (<xref ref-type="fig" rid="fig1">Figure 1d,e</xref>). Interestingly, clonotypes expanding after day 15 were significantly biased towards the CD4<sup>+</sup> phenotype, while contracting clones had balanced CD4/CD8 phenotype fractions in both donors (Fisher’s exact test, <inline-formula><mml:math id="inf1"><mml:mrow><mml:mi>p</mml:mi><mml:mo>&lt;</mml:mo><mml:mn>0.01</mml:mn></mml:mrow></mml:math></inline-formula> for both donors). A recent study by <xref ref-type="bibr" rid="bib23">Parrot et al., 2020</xref> reported activation of mucosal-associated invariant T (MAIT) cells in COVID-19 patients. MAIT cells are innate-like T cells recognising bacterial metabolites with TCRs featuring an invariant TCRalpha chain. We used a set of 121 unique MAIT TCRalpha amino acid sequences from <xref ref-type="bibr" rid="bib15">Loh et al., 2020</xref> to check whether MAIT cells contributed significantly to contracting or expanding clonotype groups identified in our study. We found that a small number of low-frequency contracting (one clonotype for each donor) and expanding (two clonotypes for each donor) TCRalpha clonotypes have MAIT invariant alpha chains, and the contribution of these clonotypes to the response was relatively small (&lt;1% of responding T cells are MAIT).</p></sec><sec id="s2-3"><title>Memory formation and pre-existing memory</title><p>On days 30, 45, and 85, we identified both contracting (<xref ref-type="fig" rid="fig2">Figure 2a–c</xref>) and expanding (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1a–c</xref>) T-cell clones in the memory subpopulations of peripheral blood. Both CD4<sup>+</sup> and CD8<sup>+</sup> responding clones were found in the CM and EM subsets; however, CD4<sup>+</sup> were more biased towards CM (with exception of donor W day 30 time point, where a considerable fraction of CD8<sup>+</sup> clones were found in CM), and CD8<sup>+</sup> clones more represented in the EMRA subset. A small number of both CD4<sup>+</sup> and CD8<sup>+</sup> responding clonotypes were also identified in the SCM subpopulation, which was previously shown to be a long-lived T-cell memory subset (<xref ref-type="bibr" rid="bib10">Fuertes Marraco et al., 2015</xref>). Note that we sequenced more cells from PBMC than from the memory subpopulations (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>), so that some low-abundant responding T-cell clones are not sampled in the memory subpopulations. Intriguingly, a number of responding CD4<sup>+</sup> clones, and fewer CD8<sup>+</sup> clones, were also represented in the repertoires of both donors 1 and 2 years before the infection. The majority of the pre-existing clones had low concentrations at pre-infection and day 85 post-infection time points, and high concentrations on day 15, suggesting that they expanded after the infection and later contracted for both donors (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>). For donor M, for whom we had previously sequenced memory subpopulations before the infection (<xref ref-type="bibr" rid="bib19">Minervina et al., 2020</xref>), we were able to identify pre-existing SARS-CoV-2-reactive CD4<sup>+</sup> clones in the CM subpopulation 1 year before the infection and a group of CD8<sup>+</sup> clones in the pre-infection EM subpopulation. Interestingly, on day 30 after infection, the majority of pre-infection CM clones were detected in the EM subpopulation, suggesting recent T-cell activation and a switch of the phenotype from memory to effector. These clones might represent memory T cells cross-reactive for other infections, for example other human coronaviruses.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Memory phenotypes of responding clonotypes contracting after day 15.</title><p>(<bold>a</bold>) A large fraction of contracting clonotypes is identified in T-cell memory subsets after infection. Bars show the fraction of contracting CD4<sup>+</sup> and CD8<sup>+</sup> TCRbeta clonotypes present in 2 year; 1 year pre-infection PBMC; in at least one of memory subpopulation sampled on day 30, day 37, and day 85 post-infection. (<bold>b, c</bold>) Responding clones are found in different memory subsets. Fraction of CD4<sup>+</sup> (left panels) and CD8<sup>+</sup> (right panels) contracting clones of donor W (<bold>b</bold>) and M (<bold>c</bold>) that were identified in each memory subpopulation repertoire at each time point. For both donors, CD4<sup>+</sup> clonotypes were found predominantly in central memory (CM) and effector memory (EM), while CD8<sup>+</sup> T cells were enriched in EMRA compartment. (<bold>c</bold>) For donor M, CD4<sup>+</sup> contracting clonotypes are also identified in memory subsets 1 year before the infection, with a bias towards the CM subpopulation and a group of CD8<sup>+</sup> clones is found in the pre-infection EM subpopulation.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63502-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Memory phenotypes of responding clonotypes expanding from day 15 to day 37.</title><p>(<bold>a</bold>) A fraction of expanding clonotypes is identified in T-cell memory subsets after infection. Bars show the fraction of expanding CD4<sup>+</sup> and CD8<sup>+</sup> TCRbeta clonotypes present in 2 year; 1 year pre-infection PBMC; and in at least one of memory subpopulation sampled on day 30 and day 37 post-infection. (<bold>b</bold>) Responding clones are found in different memory subsets. For both W (<bold>b</bold>) and M (<bold>c</bold>) donors, CD4<sup>+</sup> clonotypes were found predominantly in central memory (CM) and effector memory (EM), while CD8<sup>+</sup> T cells were also present in EMRA.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63502-fig2-figsupp1-v2.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>Dynamics of pre-existing SARS-CoV-2 responding clones.</title><p>The fraction of pre-existing (identified in −1 year and/or −2 year time point pre-infection) contracting (<bold>a</bold>) and expanding (<bold>b</bold>) TCRbeta clonotypes in the total repertoire (corresponding to the fraction of responding cells of all T cells) is plotted in log-scale for all reactive clones (left) and reactive clones with the CD4 (middle) and the CD8 phenotype (right).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63502-fig2-figsupp2-v2.tif"/></fig></fig-group><p>A search for TCRbeta amino acid sequences of responding clones in VDJdb (<xref ref-type="bibr" rid="bib2">Bagaev et al., 2020</xref>) — a database of TCRs with known specificities — resulted in essentially no overlap with TCRs not specific for SARS-CoV-2 epitopes: only two clonotypes matched. One match corresponded to the cytomegalovirus epitope presented by the HLA-A*03 MHC allele, which is absent in both donors (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>), and a second match was for Influenza A virus epitope presented by HLA-A*02 allele. The absence of matches suggests that contracting and expanding clones are unlikely to be specific for immunodominant epitopes of common pathogens covered in VDJdb. We next asked if we could map specificites of our responding clones to SARS-CoV-2 epitopes.</p></sec><sec id="s2-4"><title>Validation by MHC tetramer-staining assay</title><p>On day 25, post-infection donor M participated in a study by <xref ref-type="bibr" rid="bib33">Shomuradova et al., 2020</xref> (as donor p1434), where his CD8<sup>+</sup> T cells were stained with a HLA-A*02:01-YLQPRTFLL MHC-I tetramer (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2b</xref>). TCRalpha and TCRbeta of FACS-sorted tetramer-positive cells were sequenced and deposited to VDJdb (see <xref ref-type="bibr" rid="bib33">Shomuradova et al., 2020</xref> for the experimental details). We matched these tetramer-specific TCR sequences to our longitudinal dataset (<xref ref-type="fig" rid="fig3">Figure 3a</xref> for TCRbeta and <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref> for TCRalpha). We found that their frequencies were very low on pre-infection time points and monotonically decreased from their peak on day 15 (<inline-formula><mml:math id="inf2"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mn>7.1</mml:mn><mml:mo>×</mml:mo><mml:msup><mml:mn>10</mml:mn><mml:mrow><mml:mo>−</mml:mo><mml:mn>4</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:mstyle></mml:math></inline-formula> fraction of bulk TCRbeta repertoire) to day 85 (<inline-formula><mml:math id="inf3"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mn>1.3</mml:mn><mml:mo>×</mml:mo><mml:msup><mml:mn>10</mml:mn><mml:mrow><mml:mo>−</mml:mo><mml:mn>5</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:mstyle></mml:math></inline-formula> fraction), in close analogy to our contracting clone set. Among the tetramer-positive clones that were abundant on day 15 (with bulk frequency <inline-formula><mml:math id="inf4"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mo>&gt;</mml:mo><mml:msup><mml:mn>10</mml:mn><mml:mrow><mml:mo>−</mml:mo><mml:mn>5</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:mstyle></mml:math></inline-formula>), 17 of 18 TCRbetas and 12 of 15 TCRalphas were independently identified as contracting by our method (as expected for TCRs specifically binding MHC-I multimer, all matching clonotypes in our datasets had a CD8<sup>+</sup> phenotype). No tetramer-positive clonotypes matched with expanding clonotypes peaking on day 37.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Distinctive TCR sequence motifs and epitope specificity of contracting CD8<sup>+</sup> T cell clones.</title><p>(<bold>a</bold>) SARS-CoV-2-specific TCRs are independently identified by clonal contraction. On day 25, donor M participated in a study by <xref ref-type="bibr" rid="bib33">Shomuradova et al., 2020</xref>, where TCR sequences responding to the HLA-A*02:01-YLQPRTFLL-tetramer T cells were determined. Here we matched the resulting tetramer-specific TCRbeta clonotypes to the longitudinal repertoire dataset obtained in the current study. Each dot corresponds to the frequency of HLA-A*02:01-YLQPRTFLL-tetramer-specific TCRbeta clonotype in bulk repertoire of donor M (donor p1434 from <xref ref-type="bibr" rid="bib33">Shomuradova et al., 2020</xref>) at each time point. Green dots correspond to clonotypes independently identified as contracting in our longitudinal dataset. Blue line shows the cumulative frequency of tetramer-specific TCRbeta clonotypes. (<bold>b, c</bold>) Analysis of TCR amino acid sequences of contracting CD8<sup>+</sup> clones reveals distinctive motifs. For each set of CD8alpha and CD8beta contracted clonotypes, we constructed a separate similarity network. Each vertex in the similarity network corresponds to a contracting clonotype. An edge indicates two or less amino acid mismatches in the CDR3 region and identical V and J segments. Networks are plotted separately for CD8alpha (<bold>b</bold>) and CD8beta (<bold>c</bold>) contracting clonotypes. Clonotypes without neighbours are not shown. Sequence logos corresponding to the largest clusters are shown under the corresponding network plots. ‘T’ on vertices indicate TCRbeta clonotypes confirmed by HLA-A*02:01-YLQPRTFLL tetramer staining. Shaded coloured circles (<bold>c</bold>) indicate clonotypes with large number of matches to CD8<sup>+</sup> TCRs recognising SARS-CoV-2 peptides pools from <xref ref-type="bibr" rid="bib35">Snyder et al., 2020</xref> (MIRA peptide dataset). Lists of peptides in YLQ and ORF7b peptide pools are shown on the right. (<bold>d</bold>) Sequence convergence among contracting clonotypes. The number of edges in each group is shown by pink dots and is compared to the distribution of that number in 1000 random samples of the same size from the relevant repertoires at day 15 (blue boxplots). (<bold>e</bold>) Fraction of TCRbeta clonotypes with matches in the MIRA dataset (coloured rectangles) out of all responding CD8<sup>+</sup> TCRbeta clonotypes in donor M on day 15.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63502-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>HLA-A*02:01-YLQPRTFLL-specific TCRs are independently identified by clonal contraction.</title><p>Each dot corresponds to the frequency of HLA-A*02:01-YLQPRTFLL-tetramer-specific TCRalpha in bulk repertoire from donor M (donor p1434 from <xref ref-type="bibr" rid="bib33">Shomuradova et al., 2020</xref>) at given time point (an estimate of fraction of tetramer+ cells of all CD3<sup>+</sup> cells). Green dots correspond to clonotypes independently identified as contracting in our longitudinal dataset. Blue line shows cumulative frequency of HLA-A*02:01-YLQPRTFLL-tetramer-specific TCRalpha clonotypes.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63502-fig3-figsupp1-v2.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>ALICE algorithm output for TCRalpha PBMC repertoire of donor M on day 15.</title><p>Similarity network shows ALICE hits (clones in repertoire with more neighbours than expected by chance), which differ by two mismatches or less in TCRalpha amino acid sequence. Darker colours indicate larger frequency of clone in the repertoire, vertex size indicates degree. The majority (54%, 99/183) of hits identified by the algorithm correspond to a single large TRAV35/TRAJ42 cluster of CD4<sup>+</sup> contracting clones also seen on <xref ref-type="fig" rid="fig4">Figure 4a</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63502-fig3-figsupp2-v2.tif"/></fig></fig-group></sec><sec id="s2-5"><title>TCR sequence motifs of responding clones</title><p>It was previously shown that TCRs recognising the same antigens frequently have highly similar TCR sequences (<xref ref-type="bibr" rid="bib6">Dash et al., 2017</xref>; <xref ref-type="bibr" rid="bib11">Glanville et al., 2017</xref>). To identify motifs in TCR amino acid sequences, we plotted similarity networks for significantly contracted (<xref ref-type="fig" rid="fig3">Figures 3b,c</xref> and <xref ref-type="fig" rid="fig4">4a,b</xref>) and expanded (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1b–e</xref>) clonotypes. The number of edges in all similarity networks except CD8<sup>+</sup> expanding clones was significantly larger than would expected by randomly sampling the same number of clonotypes from the corresponding repertoire (<xref ref-type="fig" rid="fig3">Figure 3d</xref> and <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1a</xref>). In both donors, we found clusters of highly similar clones in both CD4<sup>+</sup> and CD8<sup>+</sup> subsets for expanding and contracting clonotypes. Clusters were largely donor specific, as expected, since our donors have dissimilar HLA alleles (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>) and thus each is likely to present a non-overlapping set of T-cell antigens. The largest cluster, described by the motif TRAV35-CAGXNYGGSQGNLIF-TRAJ42, was identified in donor M’s CD4<sup>+</sup>-contracting alpha chains. Clones from this cluster constituted 16.3% of all of donor M’s CD4<sup>+</sup>-responding cells on day 15, suggesting a response to an immunodominant CD4<sup>+</sup> epitope in the SARS-CoV-2 proteome. The high similarity of the TCR sequences of responding clones in this cluster allowed us to independently identify motifs from donor M’s CD4 alpha contracting clones using the ALICE algorithm (<xref ref-type="bibr" rid="bib27">Pogorelyy et al., 2019</xref>; <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref>). While the time-dependent methods (<xref ref-type="fig" rid="fig1">Figure 1</xref>) identify abundant clones, the ALICE approach is complementary to both edgeR and NoisET as it identifies clusters of T cells with similar sequences independent of their individual abundances.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Analysis of TCR amino acid sequences of CD4<sup>+</sup>contracting clones reveals distinctive motifs.</title><p>(<bold>a</bold>) Each vertex in the similarity network corresponds to a contracting clonotype. An edge indicates two or less amino acid mismatches in the CDR3 region (and identical V and J segments). Networks are plotted separately for CD4alpha (<bold>a</bold>) and CD4beta (<bold>b</bold>) contracting clonotypes. Clonotypes without neighbours are not shown. Sequence logos corresponding to the largest clusters are shown under the corresponding network plots. (<bold>c, d</bold>) Clonotypes forming the two largest motifs are significantly more clonally expanded (p&lt;0.001, one-sided t-test) in a cohort of COVID-19 patients (<xref ref-type="bibr" rid="bib35">Snyder et al., 2020</xref>) than in a cohort of control donors (<xref ref-type="bibr" rid="bib9">Emerson et al., 2017</xref>). Each dot corresponds to the total frequency of clonotypes from motifs shaded on (<bold>b</bold>) in the TCRbeta repertoire of a given donor. Coloured dots show donors predicted to share HLA-DRB1*07:01 allele with donor W (<bold>c</bold>) or HLA-DRB1*03:01-DQB1*02:01 haplotype with donor M (<bold>d</bold>).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63502-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Expanding CD4<sup>+ </sup>(but not CD8<sup>+</sup>) clonotypes show unexpected TCRalpha and TCRbeta sequence convergence.</title><p>(<bold>a</bold>) For each set of CD4alpha, CD4beta, CD8alpha, and CD8beta expanded clonotypes, we constructed separate similarity networks. Each vertex in the similarity network corresponds to an expanding clonotype. An edge indicates two or less amino acid mismatches in the CDR3 region and identical V and J segments. The number of edges in each group is shown by pink dots and is compared to the distribution of that number in 1000 random samples of the same size from the relevant repertoires at day 37 (blue boxplots). (<bold>b–e</bold>) Analysis of TCR amino acid sequences of expanding clones reveal distinctive motifs. Networks are plotted separately for CD8alpha (<bold>b</bold>), CD8beta (<bold>c</bold>), CD4alpha (<bold>d</bold>), and CD4beta (<bold>e</bold>) expanding clonotypes. Clonotypes without neighbours are not shown. Sequence logos corresponding to the largest clusters are shown under the corresponding network plots.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63502-fig4-figsupp1-v2.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>Identification of COVID-19 patients by frequency of TCR motifs from contracting CD4<sup>+</sup> clones from donors M (<bold>a</bold>) and W (<bold>b</bold>).</title><p>Receiver operating characteristic (ROC) curves for classifying TCRbeta repertoires from COVID cohort vs control by cumulative frequency of clones from CD4beta motifs. Blue curve shows ROC curve (area under the ROC or AUROC = 0.8) for the classification of control and COVID donors predicted to be DRB1*03:01-DQB1*02:01 haplotype positive with motif from donor M. Red curve shows ROC curve (AUROC = 0.79) for classification of control and COVID donors predicted to be DRB1*07:01 positive using motif from donor W. Grey ROC curves show classifier performance on all donors, irrespective of HLA allele matching (AUROC = 0.53 for (<bold>a</bold>) and AUROC = 0.57 for (<bold>b</bold>)).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63502-fig4-figsupp2-v2.tif"/></fig></fig-group></sec><sec id="s2-6"><title>Mapping TCR motifs to SARS-CoV-2 epitopes</title><p>In CD8<sup>+</sup> T cells, three clusters of highly similar TCRbeta clonotypes in donor M and one cluster of TCRalpha clonotypes correspond to YLQPRTFLL-tetramer-specific TCR sequences described above. To map additional specificities for CD8<sup>+</sup> TCRbetas, we used a large set of SARS-CoV-2-peptide-specific TCRbeta sequences from <xref ref-type="bibr" rid="bib35">Snyder et al., 2020</xref> obtained using Multiplex Identification of Antigen-specific T-cell Receptors Assay (MIRA) with combinatorial peptide pools (<xref ref-type="bibr" rid="bib13">Klinger et al., 2015</xref>). For each responding CD8<sup>+</sup> TCRbeta, we searched for the identical or highly similar (same VJ combination, up to one mismatch in CDR3aa) TCRbeta sequences specific for given SARS-CoV-2 peptides. A TCRbeta sequence from our set was considered mapped to a given peptide if it had at least two highly similar TCRbeta sequences specific for this peptide in the MIRA experiment. This procedure yielded unambiguous matches for 32 CD8<sup>+</sup> TCRbetas – just one clonotype was paired to two peptide pools (<xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>). The vast majority of matches to MIRA corresponded to groups of contracting clones. As expected, we found that all clusters corresponding to HLA-A*02:01-YLQPRTFLL MHC-I tetramer-specific TCRs were matched to the peptide pool YLQPRTFL,YLQPRTFLL,YYVGYLQPRTF in the MIRA dataset. Another large group of matches corresponded to the HLA-B*15:01-restricted (<xref ref-type="bibr" rid="bib37">Stamatakis et al., 2020</xref>) NQKLIANQF epitope. Interestingly, clonotypes corresponging to this cluster together made up 21% of the CD8<sup>+</sup> immune response on day 15, suggesting immunodominance of this epitope. Two TCRbeta clonotypes mapped to this epitope were identified in Effector Memory subset 1 year before the infection, suggesting potential cross-reactive response. We speculate that this response might be initially triggered by NQKLIANAF, a homologous HLA-B*15:01 epitope from HKU1 or OC43, common human betacoronaviruses. Importantly, no matches for the NQKLIANQF epitope were observed among contracting or expanding clonotypes of HLA-B*15-negative donor W (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). To predict potential pairings between TCRalpha and TCRbeta motifs, we used a method of alpha/beta clonal trajectory matching described in <xref ref-type="bibr" rid="bib19">Minervina et al., 2020</xref> (see Materials and methods for details). We found consistent pairing between one of the motifs in TCRalpha to the largest motif in TCRbeta T cells, which is associated with HLA-B*15:01-NQKLIANQF.</p></sec><sec id="s2-7"><title>Validation of CD4<sup>+</sup> COVID-19 HLA-restricted specificity by cohort association analysis</title><p>At the time of writing, no data on TCR sequences specific to MHC-II class epitopes exist to map specificities of CD4<sup>+</sup> T cells in a similar way as we did with MIRA-specific TCRs. However, a recently published database of 1414 bulk TCRbeta repertoires from COVID-19 patients allowed us to confirm the SARS-CoV-2 specificity of contracting clones indirectly. Public TCRbeta sequences that can recognise SARS-CoV-2 epitopes are expected to be clonally expanded and thus sampled more frequently in the repertoires of COVID-19 patients than in control donors. In <xref ref-type="fig" rid="fig4">Figure 4c,d</xref>, we show that the total frequency of TCRbeta sequences forming the largest cluster in donor M (<xref ref-type="fig" rid="fig4">Figure 4c</xref>) and donor W (<xref ref-type="fig" rid="fig4">Figure 4d</xref>) is significantly larger in the COVID-19 cohort than in the healthy donor cohort from <xref ref-type="bibr" rid="bib9">Emerson et al., 2017</xref>, suggesting antigen-dependent clonal expansion. We hypothesized that the difference between control and COVID-19 donors in motif abundance should be even larger if we restrict the analysis to donors sharing the HLA allele that presents the epitope. Unfortunately, HLA-typing information is not yet available for the COVID-19 cohort. However, using sets of HLA-associated TCRbeta sequences from <xref ref-type="bibr" rid="bib8">DeWitt et al., 2018</xref>, we could build a simple classifier to predict the HLA alleles of donors from both the control and COVID-19 cohorts exploiting the presence of TCRbeta sequences associated with certain HLA alleles (see Materials and methods for details). We found that the CD4<sup>+</sup> TCRbeta motif from donor W occurs preferentially in donors predicted to have DRB1*07:01 allele, while the motif from donor M appears to be associated with HLA-DRB1*03:01-DQB1*02:01 haplotype. The frequency of sequences corresponding to these motifs can then be used to identify SARS-CoV-2 infected donors with matching HLA alleles (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>).</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Using longitudinal repertoire sequencing, we identified a group of CD4<sup>+</sup> and CD8<sup>+</sup> T cell clones that contract after recovery from a SARS-CoV-2 infection. Our response timelines agree with T-cell dynamics reported by <xref ref-type="bibr" rid="bib39">Thevarajan et al., 2020</xref> for mild COVID-19, as well as with dynamics of T-cell response to live vaccines (<xref ref-type="bibr" rid="bib18">Miller et al., 2008</xref>). We further mapped the specificities of contracting CD8<sup>+</sup> T cells using sequences of SARS-CoV-2-specific T cells identified with tetramer staining in the same donor, as well as the large set of SARS-CoV-2 peptide stimulated TCRbeta sequences from <xref ref-type="bibr" rid="bib35">Snyder et al., 2020</xref>. For large CD4<sup>+</sup> TCRbeta motifs, we show strong association with COVID-19 by analysing the occurrence patterns and frequencies of these sequences in a large cohort of COVID-19 patients. Surprisingly, in both donors, we also identified a group of predominantly CD4<sup>+</sup> clonotypes that expanded from day 15 to day 37 after the infection. One possible explanation for this second wave of expansion is the priming of CD4<sup>+</sup> T cells by antigen-specific B cells, but there might be other mechanisms such as the migration of SARS-CoV-2-specific T cells from lymphoid organs or bystander activation of non-SARS-CoV-2 specific T cells. It is also possible that later expanding T cells are triggered by another infection, simultaneously and asymptomatically occurring in both donors around day 30. In contrast to the first wave of response identified by contracting clones, for now we do not have confirmation that this second wave of expansion corresponds to SARS-CoV-2-specific T cells. The accumulation of TCR sequences for CD4<sup>+</sup> SARS-CoV-2 epitope-specific T cells may further address this question. We showed that a large fraction of putatively SARS-CoV-2-reactive T cell clones are later found in memory subpopulations and remain there at least 3 months after infection. Importantly, some of responding clones are found in long-lived stem cell-like memory (SCM) subset, as also reported for SARS-CoV-2 convalescent patients in <xref ref-type="bibr" rid="bib32">Sekine et al., 2020</xref>. A subset of CD4<sup>+</sup> clones were identified in pre-infection central memory subsets, and a subset of CD8<sup>+</sup> T cells were found in effector memory. Among these are CD8<sup>+</sup> clones recognising NQKLIANQF, an immunodominant HLA-B*15:01 restricted SARS-CoV-2 epitope, for which homologous epitope differing by 1 aa mismatch exists in common human betacoronaviruses. The presence of SARS-CoV-2 cross-reactive CD4<sup>+</sup> T cells in healthy individuals was recently demonstrated (<xref ref-type="bibr" rid="bib5">Braun et al., 2020</xref>; <xref ref-type="bibr" rid="bib12">Grifoni et al., 2020</xref>; <xref ref-type="bibr" rid="bib14">Le Bert et al., 2020</xref>; <xref ref-type="bibr" rid="bib17">Meckiff et al., 2020</xref>; <xref ref-type="bibr" rid="bib1">Bacher et al., 2020</xref>; <xref ref-type="bibr" rid="bib24">Peng et al., 2020</xref>). Our data further suggests that cross-reactive CD4<sup>+</sup> and CD8<sup>+</sup> T cells can participate in the response in vivo. It is interesting to ask whether the presence of cross-reactive T cells before infection is linked to the mildness of the disease (with predicted HLA-B*15:01 cross-reactive epitope described above as a good starting point). Larger studies with cohorts of severe and mild cases with pre-infection time points are needed to address this question.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th>Reagent type (species) or resource</th><th>Designation</th><th>Source or reference</th><th>Identifiers</th><th>Additional information</th></tr></thead><tbody><tr><td>Antibody</td><td>Anti-CD3-FITC (mouse monoclonal)</td><td>eBioscience</td><td>CAT# 11-0038-42</td><td>FACS (5 µl per test)</td></tr><tr><td>Antibody</td><td>Anti-CD45RA-eFluor450 (mouse monoclonal)</td><td>eBioscience</td><td>CAT# 48-0458-42</td><td>FACS (5 µl per test)</td></tr><tr><td>Antibody</td><td>Anti-CCR7-APC (rat monoclonal)</td><td>eBioscience</td><td>CAT# 17-1979-42</td><td>FACS (5 µl per test)</td></tr><tr><td>Antibody</td><td>Anti-CD95-PE (mouse monoclonal)</td><td>eBioscience</td><td>CAT# 12-0959-42</td><td>FACS (5 µl per test)</td></tr><tr><td>Commercial assay or kit</td><td>Dynabeads CD4 Positive Isolation Kit</td><td>Invitrogen</td><td>CAT# 11331D</td><td/></tr><tr><td>Commercial assay or kit</td><td>Dynabeads CD8 Positive Isolation Kit</td><td>Invitrogen</td><td>CAT# 11333D</td><td/></tr></tbody></table></table-wrap><sec id="s4-1"><title>Donors and blood samples</title><p>Peripheral blood samples from two young healthy adult volunteers, donor W (female) and donor M (male), were collected with written informed consent in a certified diagnostics laboratory. Both donors gave written informed consent to participate in the study under the declaration of Helsinki. HLA alleles of both donors (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>) were determined by an in-house cDNA high-throughput sequencing method.</p></sec><sec id="s4-2"><title>SARS-CoV-2 S-RBD domain-specific ELISA</title><p>An ELISA assay kit developed by the National Research Centre for Hematology was used for detection of anti-S-RBD IgG according to the manufacturer’s protocol. The relative IgG level (OD/CO) was calculated by dividing the OD (optical density) values by the mean OD value of the cut-off positive control serum supplied with the Kit (CO). OD values of d37, d45, and d85 samples for donor M exceeded the limit of linearity for the Kit. In order to properly compare the relative IgG levels between d30, d37, d45, and d85, these samples were diluted 1:400 instead of 1:100; the ratios d37:d30 and d45:d30 and d85:d30 were calculated and used to calculate the relative IgG level of d37, d45, and d85 by multiplying d30 OD/CO value by the corresponding ratio. Relative anti-S-RBD IgM level was calculated using the same protocol with anti-human IgM-HRP-conjugated secondary antibody. Since the control cut-off serum for IgM was not available from the Kit, in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1b</xref>, we show OD values for nine biobanked pre-pandemic serum samples from healthy donors.</p></sec><sec id="s4-3"><title>Isolation of PBMCs and T-cell subpopulations</title><p>PBMCs were isolated with the Ficoll-Paque density gradient centrifugation protocol. CD4<sup>+</sup> and CD8<sup>+</sup> T cells were isolated from PBMCs with Dynabeads CD4<sup>+</sup>- and CD8<sup>+</sup>-positive selection kits (Invitrogen), respectively. For isolation of EM, EMRA, CM, and SCM memory subpopulations, we stained PBMCs with the following antibody mix: anti-CD3-FITC (UCHT1, eBioscience), anti-CD45RA-eFluor450 (HI100, eBioscience), anti-CCR7-APC (3D12, eBioscience), and anti-CD95-PE (DX2, eBioscience). Cell sorting was performed on FACS Aria III, and all four isolated subpopulations were lysed with Trizol reagent immediately after sorting.</p></sec><sec id="s4-4"><title>TCR library preparation and sequencing</title><p>TCRalpha and TCRbeta cDNA libraries preparation was performed as previously described in <xref ref-type="bibr" rid="bib25">Pogorelyy et al., 2017</xref>. RNA was isolated from each sample using Trizol reagent according to the manufacturer’s instructions. A universal primer binding site, sample barcode, and unique molecular identifier (UMI) sequences were introduced using the 5′RACE technology with TCRalpha and TCRbeta constant segment-specific primers for cDNA synthesis. cDNA libraries were amplified in two PCR steps, with the introduction of the second sample barcode and Illumina TruSeq adapter sequences at the second PCR step. Libraries were sequenced using the Illumina NovaSeq platform (2 × 150 bp read length).</p></sec><sec id="s4-5"><title>TCR repertoire data analysis</title><sec id="s4-5-1"><title>Raw data preprocessing</title><p>Raw sequencing data was demultiplexed, and UMI-guided consensuses were built using migec v.1.2.7 (<xref ref-type="bibr" rid="bib34">Shugay et al., 2014</xref>). Resulting UMI consensuses were aligned to V and J genomic templates of the TRA and TRB locus and assembled into clonotypes with mixcr v.2.1.11 (<xref ref-type="bibr" rid="bib4">Bolotin et al., 2015</xref>). See <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref> for the number of cells, UMIs, and unique clonotypes for each sample.</p></sec><sec id="s4-5-2"><title>Identification of clonotypes with active dynamics</title><p>Principal component analysis (PCA) of clonal trajectories was performed as described before <xref ref-type="bibr" rid="bib19">Minervina et al., 2020</xref>. First, we selected clones that were present among the top 1000 abundant in any of post-infection PBMC repertoires, including biological replicates, i.e. considered clone abundant if it was found within top 1000 most abundant clonotypes in at least one of the replicate samples at one time point. Next, for each such abundant clone, we calculated its frequency at each post-infection time point and divided this frequency by the maximum frequency of this clone for normalization. Then we performed PCA on the resulting normalized clonal trajectory matrix and identified three clusters of trajectories with hierarchical clustering with average linkage, using Euclidean distances between trajectories. We identify statistically significant contractions and expansions with edgeR as previously described (<xref ref-type="bibr" rid="bib26">Pogorelyy et al., 2018</xref>), using false discovery rate-adjusted <inline-formula><mml:math id="inf5"><mml:mrow><mml:mi>p</mml:mi><mml:mo>&lt;</mml:mo><mml:mn>0.01</mml:mn></mml:mrow></mml:math></inline-formula> and log<sub>2</sub> fold-change threshold of 1. NoisET implements the Bayesian detection method described in <xref ref-type="bibr" rid="bib28">Puelma Touzel et al., 2020</xref>. Briefly, a two-step noise model accounting for cell sampling and expression noise is inferred from replicates, and a second model of expansion is learned from the two time points to be compared. The procedure outputs the posterior probability of expansion or contraction and the median estimated log<sub>2</sub> fold change, whose thresholds are set to 0.05 and 1, respectively.</p></sec><sec id="s4-5-3"><title>Mapping of COVID-19-associated TCRs to the MIRA database</title><p>TCRbeta sequences from T cells specific for SARS-CoV-2 peptide pools MIRA (ImmuneCODE release 2) were downloaded from <ext-link ext-link-type="uri" xlink:href="https://clients.adaptivebiotech.com/pub/covid-2020">https://clients.adaptivebiotech.com/pub/covid-2020</ext-link>. V and J genomic templates were aligned to TCR nucleotide sequences from the MIRA database using mixcr 2.1.11. We consider a TCRbeta from MIRA matched to a TCRbeta from our data, if it had the same V and J and at most one mismatch in CDR3 amino acid sequence. We consider a TCRbeta sequence mapped to an epitope if it has at least two identical or highly similar (same V, J and up to one mismatch in CDR3 amino acid sequence) TCRbeta clonotypes reactive for this epitope in the MIRA database.</p></sec><sec id="s4-5-4"><title>Computational alpha/beta pairing by clonal trajectories</title><p>Computational alpha/beta pairing was performed as described in <xref ref-type="bibr" rid="bib19">Minervina et al., 2020</xref>. For each TCRbeta, we determine the TCRalpha with the closest clonal trajectory (<xref ref-type="supplementary-material" rid="supp3">Supplementary files 3</xref> and <xref ref-type="supplementary-material" rid="supp5">5</xref>). We observe no stringent pairings between TCRbeta and TCRbeta motifs with exception of two contracting CD8 TCRbeta clusters: TRBV7-2/TRBJ1-2 NQKLIANQF-associated clones from donor M paired to TRAV21/TRAJ40 alphas from the same cluster (CASSLEDTNYGYTF-CAVHSSGTYKYIF and CASSLEDTIYGYTF-CAALTSGTYKYIF), and TRBV7-9/TRBJ2-3 beta cluster paired to largest alpha cluster (CASSPTGRGRTDTQYF-CAYRSGGSEKLVF and CASSPTGRGGTDTQYF-CAYRRPGGEKLTF).</p></sec><sec id="s4-5-5"><title>Computational prediction of HLA types</title><p>To predict HLA types from TCR repertoires of COVID-19 cohort, we used sets of HLA-associated TCR sequences from <xref ref-type="bibr" rid="bib8">DeWitt et al., 2018</xref>. We use TCRbeta repertoires of 666 donors from cohort from <xref ref-type="bibr" rid="bib9">Emerson et al., 2017</xref>, for which HLA-typing information is available in <xref ref-type="bibr" rid="bib8">DeWitt et al., 2018</xref> as a training set to fit logistic regression model, where the presence or absense of given HLA allele is an outcome, and the number of allele-associated sequences in repertoire, as well as the total number of unique sequences in the repertoire, are the predictors. A separate logistic regression model was fitted for each set of HLA-associated sequences from <xref ref-type="bibr" rid="bib8">DeWitt et al., 2018</xref> and then used to predict the probability <inline-formula><mml:math id="inf6"><mml:mi>p</mml:mi></mml:math></inline-formula> that a donor from the COVID-19 cohort has this allele. Donors with <inline-formula><mml:math id="inf7"><mml:mrow><mml:mi>p</mml:mi><mml:mo mathvariant="normal">&lt;</mml:mo><mml:mn mathvariant="normal">0.2</mml:mn></mml:mrow></mml:math></inline-formula> were considered negative for a given allele.</p></sec></sec><sec id="s4-6"><title>Data availability</title><p>Raw sequencing data are deposited to the Short Read Archive (SRA) accession: PRJNA633317. Processed TCRalpha and TCRbeta repertoire datasets, resulting repertoires of SARS-CoV-2-reactive clones, and raw data preprocessing instructions can be accessed from: <ext-link ext-link-type="uri" xlink:href="https://github.com/pogorely/Minervina_COVID">https://github.com/pogorely/Minervina_COVID</ext-link>; copy archived at https://archive.softwareheritage.org/swh:1:rev:d5b3953d3739f21a1ccc23114bfffa002e11951e/.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>The study was supported by RSF 20-15-00351. ER and AF are supported by the DFG Excellence Cluster Precision Medicine in Chronic Inflammation (Exc2167) and the DFG grant n. 4096610003, MBK, TM, and AMW are supported by European Research Council COG 724208. IZM is supported by RFBR 19-54-12011 and 18-29-09132. DMC is supported by the grant from Ministry of Science and Higher Education of the Russian Federation 075-15-2019-1789.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf2"><p>Senior editor, <italic>eLife</italic></p></fn><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Software, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Validation, Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con3"><p>Validation, Investigation, Visualization, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con4"><p>Software, Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con5"><p>Resources, Investigation, Methodology, Project administration, Writing - review and editing</p></fn><fn fn-type="con" id="con6"><p>Resources, Supervision, Funding acquisition, Methodology, Project administration, Writing - review and editing</p></fn><fn fn-type="con" id="con7"><p>Resources, Supervision, Funding acquisition, Project administration</p></fn><fn fn-type="con" id="con8"><p>Resources, Supervision, Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con9"><p>Conceptualization, Resources, Supervision, Funding acquisition, Methodology, Project administration, Writing - review and editing</p></fn><fn fn-type="con" id="con10"><p>Conceptualization, Formal analysis, Supervision, Investigation, Methodology, Writing - original draft, Project administration, Writing - review and editing</p></fn><fn fn-type="con" id="con11"><p>Conceptualization, Formal analysis, Supervision, Funding acquisition, Investigation, Methodology, Writing - original draft, Project administration, Writing - review and editing</p></fn><fn fn-type="con" id="con12"><p>Conceptualization, Resources, Supervision, Funding acquisition, Methodology, Project administration, Writing - review and editing</p></fn><fn fn-type="con" id="con13"><p>Conceptualization, Data curation, Software, Formal analysis, Supervision, Investigation, Methodology, Writing - original draft, Project administration, Writing - review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other" id="fn1"><p>Human subjects: All subjects gave written informed consent in accordance with the Declaration of Helsinki. The study protocol was approved by the Pirogov Russian National Research Medical University local ethics committee (#194 granted on March 16, 2020).</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>List of all TCRbeta and TCRalpha libraries produced in this study.</title></caption><media mime-subtype="tab-separated-values" mimetype="text" xlink:href="elife-63502-supp1-v2.tsv"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>HLA-typing results for donors M and W.</title></caption><media mime-subtype="tab-separated-values" mimetype="text" xlink:href="elife-63502-supp2-v2.tsv"/></supplementary-material><supplementary-material id="supp3"><label>Supplementary file 3.</label><caption><title>List of TCRbeta clonotypes contracting from day 15 to day 85.</title></caption><media mime-subtype="tab-separated-values" mimetype="text" xlink:href="elife-63502-supp3-v2.tsv"/></supplementary-material><supplementary-material id="supp4"><label>Supplementary file 4.</label><caption><title>List of TCRalpha clonotypes contracting from day 15 to day 85.</title></caption><media mime-subtype="tab-separated-values" mimetype="text" xlink:href="elife-63502-supp4-v2.tsv"/></supplementary-material><supplementary-material id="supp5"><label>Supplementary file 5.</label><caption><title>List of TCRbeta clonotypes expanding from day 15 to day 37.</title></caption><media mime-subtype="tab-separated-values" mimetype="text" xlink:href="elife-63502-supp5-v2.tsv"/></supplementary-material><supplementary-material id="supp6"><label>Supplementary file 6.</label><caption><title>List of TCRalpha clonotypes expanding from day 15 to day 37.</title></caption><media mime-subtype="tab-separated-values" mimetype="text" xlink:href="elife-63502-supp6-v2.tsv"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-63502-transrepform-v2.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>Raw sequencing data are deposited to the Short Read Archive (SRA) accession: PRJNA633317. Resulting repertoires of SARS-CoV-2-reactive clones can be found in SI Tables 3-6 and also accessed from: <ext-link ext-link-type="uri" xlink:href="https://github.com/pogorely/Minervina_COVID">https://github.com/pogorely/Minervina_COVID</ext-link> (Copy archived at <ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:rev:d5b3953d3739f21a1ccc23114bfffa002e11951e/">https://archive.softwareheritage.org/swh:1:rev:d5b3953d3739f21a1ccc23114bfffa002e11951e/</ext-link>). Processed TCRalpha and TCRbeta repertoire datasets are available at : <ext-link ext-link-type="uri" xlink:href="https://zenodo.org/record/3835955">https://zenodo.org/record/3835955</ext-link>.</p><p>The following datasets were generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Minervina</surname><given-names>AA</given-names></name><name><surname>Pogorelyy</surname><given-names>MV</given-names></name><name><surname>Komech</surname><given-names>EA</given-names></name><name><surname>Karnaukhov</surname><given-names>VK</given-names></name><name><surname>Bacher</surname><given-names>P</given-names></name><name><surname>Rosati</surname><given-names>E</given-names></name><name><surname>Franke</surname><given-names>A</given-names></name><name><surname>Chudakov</surname><given-names>DM</given-names></name><name><surname>Mamedov</surname><given-names>IZ</given-names></name><name><surname>Lebedev</surname><given-names>YB</given-names></name><name><surname>Mora</surname><given-names>T</given-names></name><name><surname>Walczak</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2020">2020</year><data-title>Longitudinal high-throughput TCR repertoire profiling reveals the dynamics of T cell memory formation after mild COVID-19 infection</data-title><source>NCBI BioProject</source><pub-id assigning-authority="NCBI" pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/bioproject/PRJNA633317/">PRJNA633317</pub-id></element-citation></p><p><element-citation id="dataset2" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Minervina</surname><given-names>AA</given-names></name><name><surname>Pogorelyy</surname><given-names>MV</given-names></name><name><surname>Komech</surname><given-names>EA</given-names></name><name><surname>Karnaukhov</surname><given-names>VK</given-names></name><name><surname>Bacher</surname><given-names>P</given-names></name><name><surname>Rosati</surname><given-names>E</given-names></name><name><surname>Franke</surname><given-names>A</given-names></name><name><surname>Chudakov</surname><given-names>DM</given-names></name><name><surname>Mamedov</surname><given-names>IZ</given-names></name><name><surname>Lebedev</surname><given-names>YB</given-names></name><name><surname>Mora</surname><given-names>T</given-names></name><name><surname>Walczak</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2020">2020</year><data-title>Longitudinal high-throughput TCR repertoire profiling reveals the dynamics of T cell memory formation after mild COVID-19 infection</data-title><source>Zenodo</source><pub-id assigning-authority="Zenodo" pub-id-type="doi">10.5281/zenodo.3835955</pub-id></element-citation></p><p>The following previously published datasets were used:</p><p><element-citation id="dataset3" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Minervina</surname><given-names>AA</given-names></name><name><surname>Pogorelyy</surname><given-names>MV</given-names></name><name><surname>Komech</surname><given-names>EA</given-names></name><name><surname>Karnaukhov</surname><given-names>VK</given-names></name><name><surname>Bacher</surname><given-names>P</given-names></name><name><surname>Rosati</surname><given-names>E</given-names></name><name><surname>Franke</surname><given-names>A</given-names></name><name><surname>Chudakov</surname><given-names>DM</given-names></name><name><surname>Mamedov</surname><given-names>IZ</given-names></name><name><surname>Lebedev</surname><given-names>YB</given-names></name><name><surname>Mora</surname><given-names>T</given-names></name><name><surname>Walczak</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2019">2019</year><data-title>Comprehensive analysis of antiviral adaptive immunity formation and reactivation down to single cell level</data-title><source>NCBI BioProject</source><pub-id assigning-authority="NCBI" pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/bioproject/PRJNA577794">PRJNA577794</pub-id></element-citation></p><p><element-citation id="dataset4" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Nolan</surname><given-names>S</given-names></name><name><surname>Vignali</surname><given-names>M</given-names></name><name><surname>Klinger</surname><given-names>M</given-names></name><name><surname>Dines</surname><given-names>J</given-names></name><name><surname>Kaplan</surname><given-names>I</given-names></name><name><surname>Svejnoha</surname><given-names>E</given-names></name><name><surname>Craft</surname><given-names>T</given-names></name><name><surname>Boland</surname><given-names>K</given-names></name><name><surname>Pesesky</surname><given-names>M</given-names></name><name><surname>Gittelman</surname><given-names>RM</given-names></name><name><surname>Snyder</surname><given-names>TM</given-names></name><name><surname>Gooley</surname><given-names>CJ</given-names></name><name><surname>Semprini</surname><given-names>S</given-names></name><name><surname>Cerchione</surname><given-names>C</given-names></name><name><surname>Mazza</surname><given-names>M</given-names></name><name><surname>Delmonte</surname><given-names>OM</given-names></name><name><surname>Dobbs</surname><given-names>K</given-names></name><name><surname>Carreño-Tarragona</surname><given-names>G</given-names></name><name><surname>Barrio</surname><given-names>S</given-names></name><name><surname>Sambri</surname><given-names>V</given-names></name><name><surname>Martinelli</surname><given-names>G</given-names></name><name><surname>Goldman</surname><given-names>J</given-names></name><name><surname>Heath</surname><given-names>JR</given-names></name><name><surname>Notarangelo</surname><given-names>LD</given-names></name><name><surname>Carlson</surname><given-names>JM</given-names></name><name><surname>Martinez-Lopez</surname><given-names>J</given-names></name><name><surname>Robins</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2020">2020</year><data-title>A large-scale database of T-cell receptor beta (TCRb) sequences and binding associations from natural and synthetic exposure to SARS-CoV-2</data-title><source>ImmuneAccess</source><pub-id assigning-authority="other" pub-id-type="doi">10.21417/ADPT2020COVID</pub-id></element-citation></p><p><element-citation id="dataset5" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Emerson</surname><given-names>R</given-names></name><name><surname>DeWitt</surname><given-names>W</given-names></name><name><surname>Vignali</surname><given-names>M</given-names></name><name><surname>Gravley</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>Osborne</surname><given-names>E</given-names></name><name><surname>Desmarais</surname><given-names>C</given-names></name><name><surname>Klinger</surname><given-names>M</given-names></name><name><surname>Carlson</surname><given-names>C</given-names></name><name><surname>Hansen</surname><given-names>J</given-names></name><name><surname>Rieder</surname><given-names>M</given-names></name><name><surname>Robins</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2017">2017</year><data-title>Immunosequencing identifies signatures of cytomegalovirus exposure history and HLA-mediated effects on the T-cell repertoire</data-title><source>ImmuneAccess</source><pub-id assigning-authority="other" pub-id-type="doi">10.21417/B7001Z</pub-id></element-citation></p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bacher</surname> <given-names>P</given-names></name><name><surname>Rosati</surname> <given-names>E</given-names></name><name><surname>Esser</surname> <given-names>D</given-names></name><name><surname>Martini</surname> <given-names>GR</given-names></name><name><surname>Saggau</surname> <given-names>C</given-names></name><name><surname>Schiminsky</surname> <given-names>E</given-names></name><name><surname>Dargvainiene</surname> <given-names>J</given-names></name><name><surname>Schröder</surname> <given-names>I</given-names></name><name><surname>Wieters</surname> <given-names>I</given-names></name><name><surname>Khodamoradi</surname> <given-names>Y</given-names></name><name><surname>Eberhardt</surname> <given-names>F</given-names></name><name><surname>Vehreschild</surname> <given-names>M</given-names></name><name><surname>Neb</surname> <given-names>H</given-names></name><name><surname>Sonntagbauer</surname> <given-names>M</given-names></name><name><surname>Conrad</surname> <given-names>C</given-names></name><name><surname>Tran</surname> <given-names>F</given-names></name><name><surname>Rosenstiel</surname> <given-names>P</given-names></name><name><surname>Markewitz</surname> <given-names>R</given-names></name><name><surname>Wandinger</surname> <given-names>KP</given-names></name><name><surname>Augustin</surname> <given-names>M</given-names></name><name><surname>Rybniker</surname> <given-names>J</given-names></name><name><surname>Kochanek</surname> <given-names>M</given-names></name><name><surname>Leypoldt</surname> <given-names>F</given-names></name><name><surname>Cornely</surname> <given-names>OA</given-names></name><name><surname>Koehler</surname> <given-names>P</given-names></name><name><surname>Franke</surname> <given-names>A</given-names></name><name><surname>Scheffold</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Low-Avidity CD4<sup>+</sup> T cell responses to SARS-CoV-2 in unexposed individuals and humans with severe COVID-19</article-title><source>Immunity</source><volume>53</volume><fpage>1258</fpage><lpage>1271</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2020.11.016</pub-id><pub-id pub-id-type="pmid">33296686</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bagaev</surname> <given-names>DV</given-names></name><name><surname>Vroomans</surname> <given-names>RMA</given-names></name><name><surname>Samir</surname> <given-names>J</given-names></name><name><surname>Stervbo</surname> <given-names>U</given-names></name><name><surname>Rius</surname> <given-names>C</given-names></name><name><surname>Dolton</surname> <given-names>G</given-names></name><name><surname>Greenshields-Watson</surname> <given-names>A</given-names></name><name><surname>Attaf</surname> <given-names>M</given-names></name><name><surname>Egorov</surname> <given-names>ES</given-names></name><name><surname>Zvyagin</surname> <given-names>IV</given-names></name><name><surname>Babel</surname> <given-names>N</given-names></name><name><surname>Cole</surname> <given-names>DK</given-names></name><name><surname>Godkin</surname> <given-names>AJ</given-names></name><name><surname>Sewell</surname> <given-names>AK</given-names></name><name><surname>Kesmir</surname> <given-names>C</given-names></name><name><surname>Chudakov</surname> <given-names>DM</given-names></name><name><surname>Luciani</surname> <given-names>F</given-names></name><name><surname>Shugay</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>VDJdb in 2019: database extension, new analysis infrastructure and a T-cell receptor motif compendium</article-title><source>Nucleic Acids Research</source><volume>48</volume><fpage>D1057</fpage><lpage>D1062</lpage><pub-id pub-id-type="doi">10.1093/nar/gkz874</pub-id><pub-id pub-id-type="pmid">31588507</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bi</surname> <given-names>Q</given-names></name><name><surname>Wu</surname> <given-names>Y</given-names></name><name><surname>Mei</surname> <given-names>S</given-names></name><name><surname>Ye</surname> <given-names>C</given-names></name><name><surname>Zou</surname> <given-names>X</given-names></name><name><surname>Zhang</surname> <given-names>Z</given-names></name><name><surname>Liu</surname> <given-names>X</given-names></name><name><surname>Wei</surname> <given-names>L</given-names></name><name><surname>Truelove</surname> <given-names>SA</given-names></name><name><surname>Zhang</surname> <given-names>T</given-names></name><name><surname>Gao</surname> <given-names>W</given-names></name><name><surname>Cheng</surname> <given-names>C</given-names></name><name><surname>Tang</surname> <given-names>X</given-names></name><name><surname>Wu</surname> <given-names>X</given-names></name><name><surname>Wu</surname> <given-names>Y</given-names></name><name><surname>Sun</surname> <given-names>B</given-names></name><name><surname>Huang</surname> <given-names>S</given-names></name><name><surname>Sun</surname> <given-names>Y</given-names></name><name><surname>Zhang</surname> <given-names>J</given-names></name><name><surname>Ma</surname> <given-names>T</given-names></name><name><surname>Lessler</surname> <given-names>J</given-names></name><name><surname>Feng</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study</article-title><source>The Lancet Infectious Diseases</source><volume>20</volume><fpage>911</fpage><lpage>919</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(20)30287-5</pub-id><pub-id pub-id-type="pmid">32353347</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bolotin</surname> <given-names>DA</given-names></name><name><surname>Poslavsky</surname> <given-names>S</given-names></name><name><surname>Mitrophanov</surname> <given-names>I</given-names></name><name><surname>Shugay</surname> <given-names>M</given-names></name><name><surname>Mamedov</surname> <given-names>IZ</given-names></name><name><surname>Putintseva</surname> <given-names>EV</given-names></name><name><surname>Chudakov</surname> <given-names>DM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>MiXCR: software for comprehensive adaptive immunity profiling</article-title><source>Nature Methods</source><volume>12</volume><fpage>380</fpage><lpage>381</lpage><pub-id pub-id-type="doi">10.1038/nmeth.3364</pub-id><pub-id pub-id-type="pmid">25924071</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Braun</surname> <given-names>J</given-names></name><name><surname>Loyal</surname> <given-names>L</given-names></name><name><surname>Frentsch</surname> <given-names>M</given-names></name><name><surname>Wendisch</surname> <given-names>D</given-names></name><name><surname>Georg</surname> <given-names>P</given-names></name><name><surname>Kurth</surname> <given-names>F</given-names></name><name><surname>Hippenstiel</surname> <given-names>S</given-names></name><name><surname>Dingeldey</surname> <given-names>M</given-names></name><name><surname>Kruse</surname> <given-names>B</given-names></name><name><surname>Fauchere</surname> <given-names>F</given-names></name><name><surname>Baysal</surname> <given-names>E</given-names></name><name><surname>Mangold</surname> <given-names>M</given-names></name><name><surname>Henze</surname> <given-names>L</given-names></name><name><surname>Lauster</surname> <given-names>R</given-names></name><name><surname>Mall</surname> <given-names>MA</given-names></name><name><surname>Beyer</surname> <given-names>K</given-names></name><name><surname>Röhmel</surname> <given-names>J</given-names></name><name><surname>Voigt</surname> <given-names>S</given-names></name><name><surname>Schmitz</surname> <given-names>J</given-names></name><name><surname>Miltenyi</surname> <given-names>S</given-names></name><name><surname>Demuth</surname> <given-names>I</given-names></name><name><surname>Müller</surname> <given-names>MA</given-names></name><name><surname>Hocke</surname> <given-names>A</given-names></name><name><surname>Witzenrath</surname> <given-names>M</given-names></name><name><surname>Suttorp</surname> <given-names>N</given-names></name><name><surname>Kern</surname> <given-names>F</given-names></name><name><surname>Reimer</surname> <given-names>U</given-names></name><name><surname>Wenschuh</surname> <given-names>H</given-names></name><name><surname>Drosten</surname> <given-names>C</given-names></name><name><surname>Corman</surname> <given-names>VM</given-names></name><name><surname>Giesecke-Thiel</surname> <given-names>C</given-names></name><name><surname>Sander</surname> <given-names>LE</given-names></name><name><surname>Thiel</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Presence of SARS-CoV-2-reactive T cells in COVID-19 patients and healthy donors</article-title><source>medRxiv</source><pub-id pub-id-type="doi">10.1101/2020.04.17.20061440</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dash</surname> <given-names>P</given-names></name><name><surname>Fiore-Gartland</surname> <given-names>AJ</given-names></name><name><surname>Hertz</surname> <given-names>T</given-names></name><name><surname>Wang</surname> <given-names>GC</given-names></name><name><surname>Sharma</surname> <given-names>S</given-names></name><name><surname>Souquette</surname> <given-names>A</given-names></name><name><surname>Crawford</surname> <given-names>JC</given-names></name><name><surname>Clemens</surname> <given-names>EB</given-names></name><name><surname>Nguyen</surname> <given-names>THO</given-names></name><name><surname>Kedzierska</surname> <given-names>K</given-names></name><name><surname>La Gruta</surname> <given-names>NL</given-names></name><name><surname>Bradley</surname> <given-names>P</given-names></name><name><surname>Thomas</surname> <given-names>PG</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Quantifiable predictive features define epitope-specific T cell receptor repertoires</article-title><source>Nature</source><volume>547</volume><fpage>89</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1038/nature22383</pub-id><pub-id pub-id-type="pmid">28636592</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeWitt</surname> <given-names>WS</given-names></name><name><surname>Emerson</surname> <given-names>RO</given-names></name><name><surname>Lindau</surname> <given-names>P</given-names></name><name><surname>Vignali</surname> <given-names>M</given-names></name><name><surname>Snyder</surname> <given-names>TM</given-names></name><name><surname>Desmarais</surname> <given-names>C</given-names></name><name><surname>Sanders</surname> <given-names>C</given-names></name><name><surname>Utsugi</surname> <given-names>H</given-names></name><name><surname>Warren</surname> <given-names>EH</given-names></name><name><surname>McElrath</surname> <given-names>J</given-names></name><name><surname>Makar</surname> <given-names>KW</given-names></name><name><surname>Wald</surname> <given-names>A</given-names></name><name><surname>Robins</surname> <given-names>HS</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Dynamics of the cytotoxic T cell response to a model of acute viral infection</article-title><source>Journal of Virology</source><volume>89</volume><fpage>4517</fpage><lpage>4526</lpage><pub-id pub-id-type="doi">10.1128/JVI.03474-14</pub-id><pub-id pub-id-type="pmid">25653453</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeWitt</surname> <given-names>WS</given-names></name><name><surname>Smith</surname> <given-names>A</given-names></name><name><surname>Schoch</surname> <given-names>G</given-names></name><name><surname>Hansen</surname> <given-names>JA</given-names></name><name><surname>Matsen</surname> <given-names>FA</given-names></name><name><surname>Bradley</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Human T cell receptor occurrence patterns encode immune history, genetic background, and receptor specificity</article-title><source>eLife</source><volume>7</volume><elocation-id>e38358</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.38358</pub-id><pub-id pub-id-type="pmid">30152754</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emerson</surname> <given-names>RO</given-names></name><name><surname>DeWitt</surname> <given-names>WS</given-names></name><name><surname>Vignali</surname> <given-names>M</given-names></name><name><surname>Gravley</surname> <given-names>J</given-names></name><name><surname>Hu</surname> <given-names>JK</given-names></name><name><surname>Osborne</surname> <given-names>EJ</given-names></name><name><surname>Desmarais</surname> <given-names>C</given-names></name><name><surname>Klinger</surname> <given-names>M</given-names></name><name><surname>Carlson</surname> <given-names>CS</given-names></name><name><surname>Hansen</surname> <given-names>JA</given-names></name><name><surname>Rieder</surname> <given-names>M</given-names></name><name><surname>Robins</surname> <given-names>HS</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Immunosequencing identifies signatures of Cytomegalovirus exposure history and HLA-mediated effects on the T cell repertoire</article-title><source>Nature Genetics</source><volume>49</volume><fpage>659</fpage><lpage>665</lpage><pub-id pub-id-type="doi">10.1038/ng.3822</pub-id><pub-id pub-id-type="pmid">28369038</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fuertes Marraco</surname> <given-names>SA</given-names></name><name><surname>Soneson</surname> <given-names>C</given-names></name><name><surname>Cagnon</surname> <given-names>L</given-names></name><name><surname>Gannon</surname> <given-names>PO</given-names></name><name><surname>Allard</surname> <given-names>M</given-names></name><name><surname>Abed Maillard</surname> <given-names>S</given-names></name><name><surname>Montandon</surname> <given-names>N</given-names></name><name><surname>Rufer</surname> <given-names>N</given-names></name><name><surname>Waldvogel</surname> <given-names>S</given-names></name><name><surname>Delorenzi</surname> <given-names>M</given-names></name><name><surname>Speiser</surname> <given-names>DE</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Long-lasting stem cell-like memory CD8<sup>+</sup> T cells with a naïve-like profile upon yellow fever vaccination</article-title><source>Science Translational Medicine</source><volume>7</volume><elocation-id>282ra48</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.aaa3700</pub-id><pub-id pub-id-type="pmid">25855494</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glanville</surname> <given-names>J</given-names></name><name><surname>Huang</surname> <given-names>H</given-names></name><name><surname>Nau</surname> <given-names>A</given-names></name><name><surname>Hatton</surname> <given-names>O</given-names></name><name><surname>Wagar</surname> <given-names>LE</given-names></name><name><surname>Rubelt</surname> <given-names>F</given-names></name><name><surname>Ji</surname> <given-names>X</given-names></name><name><surname>Han</surname> <given-names>A</given-names></name><name><surname>Krams</surname> <given-names>SM</given-names></name><name><surname>Pettus</surname> <given-names>C</given-names></name><name><surname>Haas</surname> <given-names>N</given-names></name><name><surname>Arlehamn</surname> <given-names>CSL</given-names></name><name><surname>Sette</surname> <given-names>A</given-names></name><name><surname>Boyd</surname> <given-names>SD</given-names></name><name><surname>Scriba</surname> <given-names>TJ</given-names></name><name><surname>Martinez</surname> <given-names>OM</given-names></name><name><surname>Davis</surname> <given-names>MM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Identifying specificity groups in the T cell receptor repertoire</article-title><source>Nature</source><volume>547</volume><fpage>94</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1038/nature22976</pub-id><pub-id pub-id-type="pmid">28636589</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grifoni</surname> <given-names>A</given-names></name><name><surname>Weiskopf</surname> <given-names>D</given-names></name><name><surname>Ramirez</surname> <given-names>SI</given-names></name><name><surname>Mateus</surname> <given-names>J</given-names></name><name><surname>Dan</surname> <given-names>JM</given-names></name><name><surname>Moderbacher</surname> <given-names>CR</given-names></name><name><surname>Rawlings</surname> <given-names>SA</given-names></name><name><surname>Sutherland</surname> <given-names>A</given-names></name><name><surname>Premkumar</surname> <given-names>L</given-names></name><name><surname>Jadi</surname> <given-names>RS</given-names></name><name><surname>Marrama</surname> <given-names>D</given-names></name><name><surname>de Silva</surname> <given-names>AM</given-names></name><name><surname>Frazier</surname> <given-names>A</given-names></name><name><surname>Carlin</surname> <given-names>AF</given-names></name><name><surname>Greenbaum</surname> <given-names>JA</given-names></name><name><surname>Peters</surname> <given-names>B</given-names></name><name><surname>Krammer</surname> <given-names>F</given-names></name><name><surname>Smith</surname> <given-names>DM</given-names></name><name><surname>Crotty</surname> <given-names>S</given-names></name><name><surname>Sette</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals</article-title><source>Cell</source><volume>181</volume><fpage>1489</fpage><lpage>1501</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.05.015</pub-id><pub-id pub-id-type="pmid">32473127</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klinger</surname> <given-names>M</given-names></name><name><surname>Pepin</surname> <given-names>F</given-names></name><name><surname>Wilkins</surname> <given-names>J</given-names></name><name><surname>Asbury</surname> <given-names>T</given-names></name><name><surname>Wittkop</surname> <given-names>T</given-names></name><name><surname>Zheng</surname> <given-names>J</given-names></name><name><surname>Moorhead</surname> <given-names>M</given-names></name><name><surname>Faham</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Multiplex identification of Antigen-Specific T cell receptors using a combination of immune assays and immune receptor sequencing</article-title><source>PLOS ONE</source><volume>10</volume><elocation-id>e0141561</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0141561</pub-id><pub-id pub-id-type="pmid">26509579</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le Bert</surname> <given-names>N</given-names></name><name><surname>Tan</surname> <given-names>AT</given-names></name><name><surname>Kunasegaran</surname> <given-names>K</given-names></name><name><surname>Tham</surname> <given-names>CYL</given-names></name><name><surname>Hafezi</surname> <given-names>M</given-names></name><name><surname>Chia</surname> <given-names>A</given-names></name><name><surname>Chng</surname> <given-names>MHY</given-names></name><name><surname>Lin</surname> <given-names>M</given-names></name><name><surname>Tan</surname> <given-names>N</given-names></name><name><surname>Linster</surname> <given-names>M</given-names></name><name><surname>Chia</surname> <given-names>WN</given-names></name><name><surname>Chen</surname> <given-names>MI</given-names></name><name><surname>Wang</surname> <given-names>LF</given-names></name><name><surname>Ooi</surname> <given-names>EE</given-names></name><name><surname>Kalimuddin</surname> <given-names>S</given-names></name><name><surname>Tambyah</surname> <given-names>PA</given-names></name><name><surname>Low</surname> <given-names>JG</given-names></name><name><surname>Tan</surname> <given-names>YJ</given-names></name><name><surname>Bertoletti</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls</article-title><source>Nature</source><volume>584</volume><fpage>457</fpage><lpage>462</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2550-z</pub-id><pub-id pub-id-type="pmid">32668444</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loh</surname> <given-names>L</given-names></name><name><surname>Gherardin</surname> <given-names>NA</given-names></name><name><surname>Sant</surname> <given-names>S</given-names></name><name><surname>Grzelak</surname> <given-names>L</given-names></name><name><surname>Crawford</surname> <given-names>JC</given-names></name><name><surname>Bird</surname> <given-names>NL</given-names></name><name><surname>Koay</surname> <given-names>HF</given-names></name><name><surname>van de Sandt</surname> <given-names>CE</given-names></name><name><surname>Moreira</surname> <given-names>ML</given-names></name><name><surname>Lappas</surname> <given-names>M</given-names></name><name><surname>Allen</surname> <given-names>EK</given-names></name><name><surname>Crowe</surname> <given-names>J</given-names></name><name><surname>Loudovaris</surname> <given-names>T</given-names></name><name><surname>Flanagan</surname> <given-names>KL</given-names></name><name><surname>Quinn</surname> <given-names>KM</given-names></name><name><surname>Rossjohn</surname> <given-names>J</given-names></name><name><surname>Thomas</surname> <given-names>PG</given-names></name><name><surname>Eckle</surname> <given-names>SBG</given-names></name><name><surname>McCluskey</surname> <given-names>J</given-names></name><name><surname>Godfrey</surname> <given-names>DI</given-names></name><name><surname>Kedzierska</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Human Mucosal-Associated invariant T cells in older individuals display expanded tcrαβ clonotypes with potent antimicrobial responses</article-title><source>The Journal of Immunology</source><volume>204</volume><fpage>1119</fpage><lpage>1133</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1900774</pub-id><pub-id pub-id-type="pmid">31988181</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mateus</surname> <given-names>J</given-names></name><name><surname>Grifoni</surname> <given-names>A</given-names></name><name><surname>Tarke</surname> <given-names>A</given-names></name><name><surname>Sidney</surname> <given-names>J</given-names></name><name><surname>Ramirez</surname> <given-names>SI</given-names></name><name><surname>Dan</surname> <given-names>JM</given-names></name><name><surname>Burger</surname> <given-names>ZC</given-names></name><name><surname>Rawlings</surname> <given-names>SA</given-names></name><name><surname>Smith</surname> <given-names>DM</given-names></name><name><surname>Phillips</surname> <given-names>E</given-names></name><name><surname>Mallal</surname> <given-names>S</given-names></name><name><surname>Lammers</surname> <given-names>M</given-names></name><name><surname>Rubiro</surname> <given-names>P</given-names></name><name><surname>Quiambao</surname> <given-names>L</given-names></name><name><surname>Sutherland</surname> <given-names>A</given-names></name><name><surname>Yu</surname> <given-names>ED</given-names></name><name><surname>da Silva Antunes</surname> <given-names>R</given-names></name><name><surname>Greenbaum</surname> <given-names>J</given-names></name><name><surname>Frazier</surname> <given-names>A</given-names></name><name><surname>Markmann</surname> <given-names>AJ</given-names></name><name><surname>Premkumar</surname> <given-names>L</given-names></name><name><surname>de Silva</surname> <given-names>A</given-names></name><name><surname>Peters</surname> <given-names>B</given-names></name><name><surname>Crotty</surname> <given-names>S</given-names></name><name><surname>Sette</surname> <given-names>A</given-names></name><name><surname>Weiskopf</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans</article-title><source>Science</source><volume>370</volume><fpage>89</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1126/science.abd3871</pub-id><pub-id pub-id-type="pmid">32753554</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meckiff</surname> <given-names>BJ</given-names></name><name><surname>Ramírez-Suástegui</surname> <given-names>C</given-names></name><name><surname>Fajardo</surname> <given-names>V</given-names></name><name><surname>Chee</surname> <given-names>SJ</given-names></name><name><surname>Kusnadi</surname> <given-names>A</given-names></name><name><surname>Simon</surname> <given-names>H</given-names></name><name><surname>Eschweiler</surname> <given-names>S</given-names></name><name><surname>Grifoni</surname> <given-names>A</given-names></name><name><surname>Pelosi</surname> <given-names>E</given-names></name><name><surname>Weiskopf</surname> <given-names>D</given-names></name><name><surname>Sette</surname> <given-names>A</given-names></name><name><surname>Ay</surname> <given-names>F</given-names></name><name><surname>Seumois</surname> <given-names>G</given-names></name><name><surname>Ottensmeier</surname> <given-names>CH</given-names></name><name><surname>Vijayanand</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Imbalance of regulatory and cytotoxic SARS-CoV-2-Reactive CD4<sup>+</sup> T Cells in COVID-19</article-title><source>Cell</source><volume>183</volume><fpage>1340</fpage><lpage>1353</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.10.001</pub-id><pub-id pub-id-type="pmid">33096020</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname> <given-names>JD</given-names></name><name><surname>van der Most</surname> <given-names>RG</given-names></name><name><surname>Akondy</surname> <given-names>RS</given-names></name><name><surname>Glidewell</surname> <given-names>JT</given-names></name><name><surname>Albott</surname> <given-names>S</given-names></name><name><surname>Masopust</surname> <given-names>D</given-names></name><name><surname>Murali-Krishna</surname> <given-names>K</given-names></name><name><surname>Mahar</surname> <given-names>PL</given-names></name><name><surname>Edupuganti</surname> <given-names>S</given-names></name><name><surname>Lalor</surname> <given-names>S</given-names></name><name><surname>Germon</surname> <given-names>S</given-names></name><name><surname>Del Rio</surname> <given-names>C</given-names></name><name><surname>Mulligan</surname> <given-names>MJ</given-names></name><name><surname>Staprans</surname> <given-names>SI</given-names></name><name><surname>Altman</surname> <given-names>JD</given-names></name><name><surname>Feinberg</surname> <given-names>MB</given-names></name><name><surname>Ahmed</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Human effector and memory CD8+ T cell responses to Smallpox and Yellow Fever Vaccines</article-title><source>Immunity</source><volume>28</volume><fpage>710</fpage><lpage>722</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2008.02.020</pub-id><pub-id pub-id-type="pmid">18468462</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minervina</surname> <given-names>AA</given-names></name><name><surname>Pogorelyy</surname> <given-names>MV</given-names></name><name><surname>Komech</surname> <given-names>EA</given-names></name><name><surname>Karnaukhov</surname> <given-names>VK</given-names></name><name><surname>Bacher</surname> <given-names>P</given-names></name><name><surname>Rosati</surname> <given-names>E</given-names></name><name><surname>Franke</surname> <given-names>A</given-names></name><name><surname>Chudakov</surname> <given-names>DM</given-names></name><name><surname>Mamedov</surname> <given-names>IZ</given-names></name><name><surname>Lebedev</surname> <given-names>YB</given-names></name><name><surname>Mora</surname> <given-names>T</given-names></name><name><surname>Walczak</surname> <given-names>AM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Primary and secondary anti-viral response captured by the dynamics and phenotype of individual T cell clones</article-title><source>eLife</source><volume>9</volume><elocation-id>e53704</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.53704</pub-id><pub-id pub-id-type="pmid">32081129</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ng</surname> <given-names>OW</given-names></name><name><surname>Chia</surname> <given-names>A</given-names></name><name><surname>Tan</surname> <given-names>AT</given-names></name><name><surname>Jadi</surname> <given-names>RS</given-names></name><name><surname>Leong</surname> <given-names>HN</given-names></name><name><surname>Bertoletti</surname> <given-names>A</given-names></name><name><surname>Tan</surname> <given-names>YJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection</article-title><source>Vaccine</source><volume>34</volume><fpage>2008</fpage><lpage>2014</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2016.02.063</pub-id><pub-id pub-id-type="pmid">26954467</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ni</surname> <given-names>L</given-names></name><name><surname>Ye</surname> <given-names>F</given-names></name><name><surname>Cheng</surname> <given-names>ML</given-names></name><name><surname>Feng</surname> <given-names>Y</given-names></name><name><surname>Deng</surname> <given-names>YQ</given-names></name><name><surname>Zhao</surname> <given-names>H</given-names></name><name><surname>Wei</surname> <given-names>P</given-names></name><name><surname>Ge</surname> <given-names>J</given-names></name><name><surname>Gou</surname> <given-names>M</given-names></name><name><surname>Li</surname> <given-names>X</given-names></name><name><surname>Sun</surname> <given-names>L</given-names></name><name><surname>Cao</surname> <given-names>T</given-names></name><name><surname>Wang</surname> <given-names>P</given-names></name><name><surname>Zhou</surname> <given-names>C</given-names></name><name><surname>Zhang</surname> <given-names>R</given-names></name><name><surname>Liang</surname> <given-names>P</given-names></name><name><surname>Guo</surname> <given-names>H</given-names></name><name><surname>Wang</surname> <given-names>X</given-names></name><name><surname>Qin</surname> <given-names>CF</given-names></name><name><surname>Chen</surname> <given-names>F</given-names></name><name><surname>Dong</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Detection of SARS-CoV-2-Specific humoral and cellular immunity in COVID-19 convalescent individuals</article-title><source>Immunity</source><volume>52</volume><fpage>971</fpage><lpage>977</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2020.04.023</pub-id><pub-id pub-id-type="pmid">32413330</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oh</surname> <given-names>HL</given-names></name><name><surname>Chia</surname> <given-names>A</given-names></name><name><surname>Chang</surname> <given-names>CX</given-names></name><name><surname>Leong</surname> <given-names>HN</given-names></name><name><surname>Ling</surname> <given-names>KL</given-names></name><name><surname>Grotenbreg</surname> <given-names>GM</given-names></name><name><surname>Gehring</surname> <given-names>AJ</given-names></name><name><surname>Tan</surname> <given-names>YJ</given-names></name><name><surname>Bertoletti</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Engineering T cells specific for a dominant severe acute respiratory syndrome coronavirus CD8 T cell epitope</article-title><source>Journal of Virology</source><volume>85</volume><fpage>10464</fpage><lpage>10471</lpage><pub-id pub-id-type="doi">10.1128/JVI.05039-11</pub-id><pub-id pub-id-type="pmid">21813600</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parrot</surname> <given-names>T</given-names></name><name><surname>Gorin</surname> <given-names>JB</given-names></name><name><surname>Ponzetta</surname> <given-names>A</given-names></name><name><surname>Maleki</surname> <given-names>KT</given-names></name><name><surname>Kammann</surname> <given-names>T</given-names></name><name><surname>Emgård</surname> <given-names>J</given-names></name><name><surname>Perez-Potti</surname> <given-names>A</given-names></name><name><surname>Sekine</surname> <given-names>T</given-names></name><name><surname>Rivera-Ballesteros</surname> <given-names>O</given-names></name><name><surname>Gredmark-Russ</surname> <given-names>S</given-names></name><name><surname>Rooyackers</surname> <given-names>O</given-names></name><name><surname>Folkesson</surname> <given-names>E</given-names></name><name><surname>Eriksson</surname> <given-names>LI</given-names></name><name><surname>Norrby-Teglund</surname> <given-names>A</given-names></name><name><surname>Ljunggren</surname> <given-names>HG</given-names></name><name><surname>Björkström</surname> <given-names>NK</given-names></name><name><surname>Aleman</surname> <given-names>S</given-names></name><name><surname>Buggert</surname> <given-names>M</given-names></name><name><surname>Klingström</surname> <given-names>J</given-names></name><name><surname>Strålin</surname> <given-names>K</given-names></name><name><surname>Sandberg</surname> <given-names>JK</given-names></name><collab>Karolinska COVID-19 Study Group</collab></person-group><year iso-8601-date="2020">2020</year><article-title>MAIT cell activation and dynamics associated with COVID-19 disease severity</article-title><source>Science Immunology</source><volume>5</volume><elocation-id>eabe1670</elocation-id><pub-id pub-id-type="doi">10.1126/sciimmunol.abe1670</pub-id><pub-id pub-id-type="pmid">32989174</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Peng</surname> <given-names>Y</given-names></name><name><surname>Mentzer</surname> <given-names>AJ</given-names></name><name><surname>Liu</surname> <given-names>G</given-names></name><name><surname>Yao</surname> <given-names>X</given-names></name><name><surname>Yin</surname> <given-names>Z</given-names></name><name><surname>Dong</surname> <given-names>D</given-names></name><name><surname>Dejnirattisai</surname> <given-names>W</given-names></name><name><surname>Rostron</surname> <given-names>T</given-names></name><name><surname>Supasa</surname> <given-names>P</given-names></name><name><surname>Liu</surname> <given-names>C</given-names></name><name><surname>López-Camacho</surname> <given-names>C</given-names></name><name><surname>Slon-Campos</surname> <given-names>J</given-names></name><name><surname>Zhao</surname> <given-names>Y</given-names></name><name><surname>Stuart</surname> <given-names>DI</given-names></name><name><surname>Paesen</surname> <given-names>GC</given-names></name><name><surname>Grimes</surname> <given-names>JM</given-names></name><name><surname>Antson</surname> <given-names>AA</given-names></name><name><surname>Bayfield</surname> <given-names>OW</given-names></name><name><surname>Hawkins</surname> <given-names>D</given-names></name><name><surname>Ker</surname> <given-names>DS</given-names></name><name><surname>Wang</surname> <given-names>B</given-names></name><name><surname>Turtle</surname> <given-names>L</given-names></name><name><surname>Subramaniam</surname> <given-names>K</given-names></name><name><surname>Thomson</surname> <given-names>P</given-names></name><name><surname>Zhang</surname> <given-names>P</given-names></name><name><surname>Dold</surname> <given-names>C</given-names></name><name><surname>Ratcliff</surname> <given-names>J</given-names></name><name><surname>Simmonds</surname> <given-names>P</given-names></name><name><surname>de Silva</surname> <given-names>T</given-names></name><name><surname>Sopp</surname> <given-names>P</given-names></name><name><surname>Wellington</surname> <given-names>D</given-names></name><name><surname>Rajapaksa</surname> <given-names>U</given-names></name><name><surname>Chen</surname> <given-names>YL</given-names></name><name><surname>Salio</surname> <given-names>M</given-names></name><name><surname>Napolitani</surname> <given-names>G</given-names></name><name><surname>Paes</surname> <given-names>W</given-names></name><name><surname>Borrow</surname> <given-names>P</given-names></name><name><surname>Kessler</surname> <given-names>BM</given-names></name><name><surname>Fry</surname> <given-names>JW</given-names></name><name><surname>Schwabe</surname> <given-names>NF</given-names></name><name><surname>Semple</surname> <given-names>MG</given-names></name><name><surname>Baillie</surname> <given-names>JK</given-names></name><name><surname>Moore</surname> <given-names>SC</given-names></name><name><surname>Openshaw</surname> <given-names>PJM</given-names></name><name><surname>Ansari</surname> <given-names>MA</given-names></name><name><surname>Dunachie</surname> <given-names>S</given-names></name><name><surname>Barnes</surname> <given-names>E</given-names></name><name><surname>Frater</surname> <given-names>J</given-names></name><name><surname>Kerr</surname> <given-names>G</given-names></name><name><surname>Goulder</surname> <given-names>P</given-names></name><name><surname>Lockett</surname> <given-names>T</given-names></name><name><surname>Levin</surname> <given-names>R</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Jing</surname> <given-names>R</given-names></name><name><surname>Ho</surname> <given-names>LP</given-names></name><name><surname>Cornall</surname> <given-names>RJ</given-names></name><name><surname>Conlon</surname> <given-names>CP</given-names></name><name><surname>Klenerman</surname> <given-names>P</given-names></name><name><surname>Screaton</surname> <given-names>GR</given-names></name><name><surname>Mongkolsapaya</surname> <given-names>J</given-names></name><name><surname>McMichael</surname> <given-names>A</given-names></name><name><surname>Knight</surname> <given-names>JC</given-names></name><name><surname>Ogg</surname> <given-names>G</given-names></name><name><surname>Dong</surname> <given-names>T</given-names></name><collab>Oxford Immunology Network Covid-19 Response T cell Consortium</collab><collab>ISARIC4C Investigators</collab></person-group><year iso-8601-date="2020">2020</year><article-title>Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent COVID-19 patients</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2020.06.05.134551</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pogorelyy</surname> <given-names>MV</given-names></name><name><surname>Elhanati</surname> <given-names>Y</given-names></name><name><surname>Marcou</surname> <given-names>Q</given-names></name><name><surname>Sycheva</surname> <given-names>AL</given-names></name><name><surname>Komech</surname> <given-names>EA</given-names></name><name><surname>Nazarov</surname> <given-names>VI</given-names></name><name><surname>Britanova</surname> <given-names>OV</given-names></name><name><surname>Chudakov</surname> <given-names>DM</given-names></name><name><surname>Mamedov</surname> <given-names>IZ</given-names></name><name><surname>Lebedev</surname> <given-names>YB</given-names></name><name><surname>Mora</surname> <given-names>T</given-names></name><name><surname>Walczak</surname> <given-names>AM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Persisting fetal clonotypes influence the structure and overlap of adult human T cell receptor repertoires</article-title><source>PLOS Computational Biology</source><volume>13</volume><elocation-id>e1005572</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1005572</pub-id><pub-id pub-id-type="pmid">28683116</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pogorelyy</surname> <given-names>MV</given-names></name><name><surname>Minervina</surname> <given-names>AA</given-names></name><name><surname>Touzel</surname> <given-names>MP</given-names></name><name><surname>Sycheva</surname> <given-names>AL</given-names></name><name><surname>Komech</surname> <given-names>EA</given-names></name><name><surname>Kovalenko</surname> <given-names>EI</given-names></name><name><surname>Karganova</surname> <given-names>GG</given-names></name><name><surname>Egorov</surname> <given-names>ES</given-names></name><name><surname>Komkov</surname> <given-names>AY</given-names></name><name><surname>Chudakov</surname> <given-names>DM</given-names></name><name><surname>Mamedov</surname> <given-names>IZ</given-names></name><name><surname>Mora</surname> <given-names>T</given-names></name><name><surname>Walczak</surname> <given-names>AM</given-names></name><name><surname>Lebedev</surname> <given-names>YB</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Precise tracking of vaccine-responding T cell clones reveals convergent and personalized response in identical twins</article-title><source>PNAS</source><volume>115</volume><fpage>12704</fpage><lpage>12709</lpage><pub-id pub-id-type="doi">10.1073/pnas.1809642115</pub-id><pub-id pub-id-type="pmid">30459272</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pogorelyy</surname> <given-names>MV</given-names></name><name><surname>Minervina</surname> <given-names>AA</given-names></name><name><surname>Shugay</surname> <given-names>M</given-names></name><name><surname>Chudakov</surname> <given-names>DM</given-names></name><name><surname>Lebedev</surname> <given-names>YB</given-names></name><name><surname>Mora</surname> <given-names>T</given-names></name><name><surname>Walczak</surname> <given-names>AM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Detecting T cell receptors involved in immune responses from single repertoire snapshots</article-title><source>PLOS Biology</source><volume>17</volume><elocation-id>e3000314</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pbio.3000314</pub-id><pub-id pub-id-type="pmid">31194732</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Puelma Touzel</surname> <given-names>M</given-names></name><name><surname>Walczak</surname> <given-names>AM</given-names></name><name><surname>Mora</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Inferring the immune response from repertoire sequencing</article-title><source>PLOS Computational Biology</source><volume>16</volume><elocation-id>e1007873</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1007873</pub-id><pub-id pub-id-type="pmid">32348312</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quinti</surname> <given-names>I</given-names></name><name><surname>Lougaris</surname> <given-names>V</given-names></name><name><surname>Milito</surname> <given-names>C</given-names></name><name><surname>Cinetto</surname> <given-names>F</given-names></name><name><surname>Pecoraro</surname> <given-names>A</given-names></name><name><surname>Mezzaroma</surname> <given-names>I</given-names></name><name><surname>Mastroianni</surname> <given-names>CM</given-names></name><name><surname>Turriziani</surname> <given-names>O</given-names></name><name><surname>Bondioni</surname> <given-names>MP</given-names></name><name><surname>Filippini</surname> <given-names>M</given-names></name><name><surname>Soresina</surname> <given-names>A</given-names></name><name><surname>Spadaro</surname> <given-names>G</given-names></name><name><surname>Agostini</surname> <given-names>C</given-names></name><name><surname>Carsetti</surname> <given-names>R</given-names></name><name><surname>Plebani</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A possible role for B cells in COVID-19? lesson from patients with agammaglobulinemia</article-title><source>Journal of Allergy and Clinical Immunology</source><volume>146</volume><fpage>211</fpage><lpage>213</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2020.04.013</pub-id><pub-id pub-id-type="pmid">32333914</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname> <given-names>MD</given-names></name><name><surname>McCarthy</surname> <given-names>DJ</given-names></name><name><surname>Smyth</surname> <given-names>GK</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>edgeR: a bioconductor package for differential expression analysis of digital gene expression data</article-title><source>Bioinformatics</source><volume>26</volume><fpage>139</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btp616</pub-id><pub-id pub-id-type="pmid">19910308</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname> <given-names>ME</given-names></name><name><surname>Varga</surname> <given-names>SM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The CD8 T cell response to respiratory virus infections</article-title><source>Frontiers in Immunology</source><volume>9</volume><elocation-id>678</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2018.00678</pub-id><pub-id pub-id-type="pmid">29686673</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sekine</surname> <given-names>T</given-names></name><name><surname>Perez-Potti</surname> <given-names>A</given-names></name><name><surname>Rivera-Ballesteros</surname> <given-names>O</given-names></name><name><surname>Strålin</surname> <given-names>K</given-names></name><name><surname>Gorin</surname> <given-names>JB</given-names></name><name><surname>Olsson</surname> <given-names>A</given-names></name><name><surname>Llewellyn-Lacey</surname> <given-names>S</given-names></name><name><surname>Kamal</surname> <given-names>H</given-names></name><name><surname>Bogdanovic</surname> <given-names>G</given-names></name><name><surname>Muschiol</surname> <given-names>S</given-names></name><name><surname>Wullimann</surname> <given-names>DJ</given-names></name><name><surname>Kammann</surname> <given-names>T</given-names></name><name><surname>Emgård</surname> <given-names>J</given-names></name><name><surname>Parrot</surname> <given-names>T</given-names></name><name><surname>Folkesson</surname> <given-names>E</given-names></name><name><surname>Rooyackers</surname> <given-names>O</given-names></name><name><surname>Eriksson</surname> <given-names>LI</given-names></name><name><surname>Henter</surname> <given-names>JI</given-names></name><name><surname>Sönnerborg</surname> <given-names>A</given-names></name><name><surname>Allander</surname> <given-names>T</given-names></name><name><surname>Albert</surname> <given-names>J</given-names></name><name><surname>Nielsen</surname> <given-names>M</given-names></name><name><surname>Klingström</surname> <given-names>J</given-names></name><name><surname>Gredmark-Russ</surname> <given-names>S</given-names></name><name><surname>Björkström</surname> <given-names>NK</given-names></name><name><surname>Sandberg</surname> <given-names>JK</given-names></name><name><surname>Price</surname> <given-names>DA</given-names></name><name><surname>Ljunggren</surname> <given-names>HG</given-names></name><name><surname>Aleman</surname> <given-names>S</given-names></name><name><surname>Buggert</surname> <given-names>M</given-names></name><collab>Karolinska COVID-19 Study Group</collab></person-group><year iso-8601-date="2020">2020</year><article-title>Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19</article-title><source>Cell</source><volume>183</volume><fpage>158</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.08.017</pub-id><pub-id pub-id-type="pmid">32979941</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shomuradova</surname> <given-names>AS</given-names></name><name><surname>Vagida</surname> <given-names>MS</given-names></name><name><surname>Sheetikov</surname> <given-names>SA</given-names></name><name><surname>Zornikova</surname> <given-names>KV</given-names></name><name><surname>Kiryukhin</surname> <given-names>D</given-names></name><name><surname>Titov</surname> <given-names>A</given-names></name><name><surname>Peshkova</surname> <given-names>IO</given-names></name><name><surname>Khmelevskaya</surname> <given-names>A</given-names></name><name><surname>Dianov</surname> <given-names>DV</given-names></name><name><surname>Malasheva</surname> <given-names>M</given-names></name><name><surname>Shmelev</surname> <given-names>A</given-names></name><name><surname>Serdyuk</surname> <given-names>Y</given-names></name><name><surname>Bagaev</surname> <given-names>DV</given-names></name><name><surname>Pivnyuk</surname> <given-names>A</given-names></name><name><surname>Shcherbinin</surname> <given-names>DS</given-names></name><name><surname>Maleeva</surname> <given-names>AV</given-names></name><name><surname>Shakirova</surname> <given-names>NT</given-names></name><name><surname>Pilunov</surname> <given-names>A</given-names></name><name><surname>Malko</surname> <given-names>DB</given-names></name><name><surname>Khamaganova</surname> <given-names>EG</given-names></name><name><surname>Biderman</surname> <given-names>B</given-names></name><name><surname>Ivanov</surname> <given-names>A</given-names></name><name><surname>Shugay</surname> <given-names>M</given-names></name><name><surname>Efimov</surname> <given-names>GA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>SARS-CoV-2 epitopes are recognized by a public and diverse repertoire of human T cell receptors</article-title><source>Immunity</source><volume>53</volume><fpage>1245</fpage><lpage>1257</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2020.11.004</pub-id><pub-id pub-id-type="pmid">33326767</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shugay</surname> <given-names>M</given-names></name><name><surname>Britanova</surname> <given-names>OV</given-names></name><name><surname>Merzlyak</surname> <given-names>EM</given-names></name><name><surname>Turchaninova</surname> <given-names>MA</given-names></name><name><surname>Mamedov</surname> <given-names>IZ</given-names></name><name><surname>Tuganbaev</surname> <given-names>TR</given-names></name><name><surname>Bolotin</surname> <given-names>DA</given-names></name><name><surname>Staroverov</surname> <given-names>DB</given-names></name><name><surname>Putintseva</surname> <given-names>EV</given-names></name><name><surname>Plevova</surname> <given-names>K</given-names></name><name><surname>Linnemann</surname> <given-names>C</given-names></name><name><surname>Shagin</surname> <given-names>D</given-names></name><name><surname>Pospisilova</surname> <given-names>S</given-names></name><name><surname>Lukyanov</surname> <given-names>S</given-names></name><name><surname>Schumacher</surname> <given-names>TN</given-names></name><name><surname>Chudakov</surname> <given-names>DM</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Towards error-free profiling of immune repertoires</article-title><source>Nature Methods</source><volume>11</volume><fpage>653</fpage><lpage>655</lpage><pub-id pub-id-type="doi">10.1038/nmeth.2960</pub-id><pub-id pub-id-type="pmid">24793455</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Snyder</surname> <given-names>TM</given-names></name><name><surname>Gittelman</surname> <given-names>RM</given-names></name><name><surname>Klinger</surname> <given-names>M</given-names></name><name><surname>May</surname> <given-names>DH</given-names></name><name><surname>Osborne</surname> <given-names>EJ</given-names></name><name><surname>Taniguchi</surname> <given-names>R</given-names></name><name><surname>Zahid</surname> <given-names>HJ</given-names></name><name><surname>Kaplan</surname> <given-names>IM</given-names></name><name><surname>Dines</surname> <given-names>JN</given-names></name><name><surname>Noakes</surname> <given-names>MN</given-names></name><name><surname>Pandya</surname> <given-names>R</given-names></name><name><surname>Chen</surname> <given-names>X</given-names></name><name><surname>Elasady</surname> <given-names>S</given-names></name><name><surname>Svejnoha</surname> <given-names>E</given-names></name><name><surname>Ebert</surname> <given-names>P</given-names></name><name><surname>Pesesky</surname> <given-names>MW</given-names></name><name><surname>De Almeida</surname> <given-names>P</given-names></name><name><surname>O'Donnell</surname> <given-names>H</given-names></name><name><surname>DeGottardi</surname> <given-names>Q</given-names></name><name><surname>Keitany</surname> <given-names>G</given-names></name><name><surname>Lu</surname> <given-names>J</given-names></name><name><surname>Vong</surname> <given-names>A</given-names></name><name><surname>Elyanow</surname> <given-names>R</given-names></name><name><surname>Fields</surname> <given-names>P</given-names></name><name><surname>Greissl</surname> <given-names>J</given-names></name><name><surname>Baldo</surname> <given-names>L</given-names></name><name><surname>Semprini</surname> <given-names>S</given-names></name><name><surname>Cerchione</surname> <given-names>C</given-names></name><name><surname>Mazza</surname> <given-names>M</given-names></name><name><surname>Delmonte</surname> <given-names>OM</given-names></name><name><surname>Dobbs</surname> <given-names>K</given-names></name><name><surname>Carreño-Tarragona</surname> <given-names>G</given-names></name><name><surname>Barrio</surname> <given-names>S</given-names></name><name><surname>Imberti</surname> <given-names>L</given-names></name><name><surname>Sottini</surname> <given-names>A</given-names></name><name><surname>Quiros-Roldan</surname> <given-names>E</given-names></name><name><surname>Rossi</surname> <given-names>C</given-names></name><name><surname>Biondi</surname> <given-names>A</given-names></name><name><surname>Bettini</surname> <given-names>LR</given-names></name><name><surname>D'Angio</surname> <given-names>M</given-names></name><name><surname>Bonfanti</surname> <given-names>P</given-names></name><name><surname>Tompkins</surname> <given-names>MF</given-names></name><name><surname>Alba</surname> <given-names>C</given-names></name><name><surname>Dalgard</surname> <given-names>C</given-names></name><name><surname>Sambri</surname> <given-names>V</given-names></name><name><surname>Martinelli</surname> <given-names>G</given-names></name><name><surname>Goldman</surname> <given-names>JD</given-names></name><name><surname>Heath</surname> <given-names>JR</given-names></name><name><surname>Su</surname> <given-names>HC</given-names></name><name><surname>Notarangelo</surname> <given-names>LD</given-names></name><name><surname>Martinez-Lopez</surname> <given-names>J</given-names></name><name><surname>Carlson</surname> <given-names>JM</given-names></name><name><surname>Robins</surname> <given-names>HS</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Magnitude and dynamics of the T-Cell response to SARS-CoV-2 infection at both individual and population levels</article-title><source>medRxiv</source><pub-id pub-id-type="doi">10.1101/2020.07.31.20165647</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soresina</surname> <given-names>A</given-names></name><name><surname>Moratto</surname> <given-names>D</given-names></name><name><surname>Chiarini</surname> <given-names>M</given-names></name><name><surname>Paolillo</surname> <given-names>C</given-names></name><name><surname>Baresi</surname> <given-names>G</given-names></name><name><surname>Focà</surname> <given-names>E</given-names></name><name><surname>Bezzi</surname> <given-names>M</given-names></name><name><surname>Baronio</surname> <given-names>B</given-names></name><name><surname>Giacomelli</surname> <given-names>M</given-names></name><name><surname>Badolato</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover</article-title><source>Pediatric Allergy and Immunology</source><volume>31</volume><fpage>565</fpage><lpage>569</lpage><pub-id pub-id-type="doi">10.1111/pai.13263</pub-id><pub-id pub-id-type="pmid">32319118</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Stamatakis</surname> <given-names>G</given-names></name><name><surname>Samiotaki</surname> <given-names>M</given-names></name><name><surname>Mpakali</surname> <given-names>A</given-names></name><name><surname>Panayotou</surname> <given-names>G</given-names></name><name><surname>Stratikos</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Generation of SARS-CoV-2 S1 spike glycoprotein putative antigenic epitopes in vitro by intracellular aminopeptidases</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2020.06.22.164681</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swain</surname> <given-names>SL</given-names></name><name><surname>McKinstry</surname> <given-names>KK</given-names></name><name><surname>Strutt</surname> <given-names>TM</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Expanding roles for CD4⁺ T cells in immunity to viruses</article-title><source>Nature Reviews Immunology</source><volume>12</volume><fpage>136</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1038/nri3152</pub-id><pub-id pub-id-type="pmid">22266691</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thevarajan</surname> <given-names>I</given-names></name><name><surname>Nguyen</surname> <given-names>THO</given-names></name><name><surname>Koutsakos</surname> <given-names>M</given-names></name><name><surname>Druce</surname> <given-names>J</given-names></name><name><surname>Caly</surname> <given-names>L</given-names></name><name><surname>van de Sandt</surname> <given-names>CE</given-names></name><name><surname>Jia</surname> <given-names>X</given-names></name><name><surname>Nicholson</surname> <given-names>S</given-names></name><name><surname>Catton</surname> <given-names>M</given-names></name><name><surname>Cowie</surname> <given-names>B</given-names></name><name><surname>Tong</surname> <given-names>SYC</given-names></name><name><surname>Lewin</surname> <given-names>SR</given-names></name><name><surname>Kedzierska</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19</article-title><source>Nature Medicine</source><volume>26</volume><fpage>453</fpage><lpage>455</lpage><pub-id pub-id-type="doi">10.1038/s41591-020-0819-2</pub-id><pub-id pub-id-type="pmid">32284614</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vabret</surname> <given-names>N</given-names></name><name><surname>Britton</surname> <given-names>GJ</given-names></name><name><surname>Gruber</surname> <given-names>C</given-names></name><name><surname>Hegde</surname> <given-names>S</given-names></name><name><surname>Kim</surname> <given-names>J</given-names></name><name><surname>Kuksin</surname> <given-names>M</given-names></name><name><surname>Levantovsky</surname> <given-names>R</given-names></name><name><surname>Malle</surname> <given-names>L</given-names></name><name><surname>Moreira</surname> <given-names>A</given-names></name><name><surname>Park</surname> <given-names>MD</given-names></name><name><surname>Pia</surname> <given-names>L</given-names></name><name><surname>Risson</surname> <given-names>E</given-names></name><name><surname>Saffern</surname> <given-names>M</given-names></name><name><surname>Salomé</surname> <given-names>B</given-names></name><name><surname>Esai Selvan</surname> <given-names>M</given-names></name><name><surname>Spindler</surname> <given-names>MP</given-names></name><name><surname>Tan</surname> <given-names>J</given-names></name><name><surname>van der Heide</surname> <given-names>V</given-names></name><name><surname>Gregory</surname> <given-names>JK</given-names></name><name><surname>Alexandropoulos</surname> <given-names>K</given-names></name><name><surname>Bhardwaj</surname> <given-names>N</given-names></name><name><surname>Brown</surname> <given-names>BD</given-names></name><name><surname>Greenbaum</surname> <given-names>B</given-names></name><name><surname>Gümüş</surname> <given-names>ZH</given-names></name><name><surname>Homann</surname> <given-names>D</given-names></name><name><surname>Horowitz</surname> <given-names>A</given-names></name><name><surname>Kamphorst</surname> <given-names>AO</given-names></name><name><surname>Curotto de Lafaille</surname> <given-names>MA</given-names></name><name><surname>Mehandru</surname> <given-names>S</given-names></name><name><surname>Merad</surname> <given-names>M</given-names></name><name><surname>Samstein</surname> <given-names>RM</given-names></name><collab>Sinai Immunology Review Project</collab></person-group><year iso-8601-date="2020">2020</year><article-title>Immunology of COVID-19: current state of the science</article-title><source>Immunity</source><volume>52</volume><fpage>910</fpage><lpage>941</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2020.05.002</pub-id><pub-id pub-id-type="pmid">32505227</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Weiskopf</surname> <given-names>D</given-names></name><name><surname>Schmitz</surname> <given-names>KS</given-names></name><name><surname>Raadsen</surname> <given-names>MP</given-names></name><name><surname>Grifoni</surname> <given-names>A</given-names></name><name><surname>Okba</surname> <given-names>NMA</given-names></name><name><surname>Endeman</surname> <given-names>H</given-names></name><name><surname>van den Akker</surname> <given-names>JPC</given-names></name><name><surname>Molenkamp</surname> <given-names>R</given-names></name><name><surname>Koopmans</surname> <given-names>MPG</given-names></name><name><surname>van Gorp</surname> <given-names>ECM</given-names></name><name><surname>Haagmans</surname> <given-names>BL</given-names></name><name><surname>de Swart</surname> <given-names>RL</given-names></name><name><surname>Sette</surname> <given-names>A</given-names></name><name><surname>de Vries</surname> <given-names>RD</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome</article-title><source>medRxiv</source><pub-id pub-id-type="doi">10.1101/2020.04.11.20062349</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname> <given-names>J</given-names></name><name><surname>Zhao</surname> <given-names>J</given-names></name><name><surname>Perlman</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice</article-title><source>Journal of Virology</source><volume>84</volume><fpage>9318</fpage><lpage>9325</lpage><pub-id pub-id-type="doi">10.1128/JVI.01049-10</pub-id><pub-id pub-id-type="pmid">20610717</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.63502.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Krishna</surname><given-names>Sandeep</given-names></name><role>Reviewing Editor</role><aff><institution>National Centre for Biological Sciences‐Tata Institute of Fundamental Research</institution><country>India</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Cowell</surname><given-names>Lindsay</given-names> </name><role>Reviewer</role><aff><institution/><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>This paper uses high throughput longitudinal TCR sequencing to understand the TCR dynamics in two persons infected with SARS-CoV-2. In particular, they find two peaks of T cell clonal expansion at 15 and 37 days post infection. The authors also identify TCR sequence motifs that are likely to be specific to SARS-CoV-2 and thereby show that some T cell clones are present pre-infection suggesting the existence of cross-reactive memory T cells prior to the infection.</p><p><bold>Decision letter after peer review:</bold></p><p>[Editors’ note: the authors submitted for reconsideration following the decision after peer review. What follows is the decision letter after the first round of review.]</p><p>Thank you for submitting your work entitled &quot;Longitudinal TCR repertoire profiling reveals the dynamics of T cell memory formation after mild COVID-19&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and a Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Phil Bradley (Reviewer #2).</p><p>Our decision has been reached after consultation between the reviewers. Based on these discussions and the individual reviews below, we regret to inform you that your work will not be considered further for publication in <italic>eLife</italic>.</p><p>While we found the questions raised in this study interesting, we concluded that the manuscript would not be suitable for <italic>eLife</italic> without substantially more evidence that the clonotypes have TCR specificity for SARS-CoV-2. The individual reviews are appended below.</p><p><italic>Reviewer #1:</italic></p><p>This work investigates the T cell receptor (TCR) repertoires of 2 individuals diagnosed with mild COVID-19 infection. The authors use high-throughput sequencing of 2 biological replicate samples obtained at each of multiple pre-infection and post-infection timepoints to identify TCRalpha and TCRbeta clonotypes that contract or expand post-infection and to investigate potential reactivation of pre-existing memory cells. This is a potentially interesting work that may provide novel insights into T cell responses to SARS-CoV-2. However, some of the specific details of the various analyses reported are not clear and I have several major concerns about the reported work.</p><p>1) The primary concern is the TCR specificity of the clonotypes that were determined to be contracting or expanding post-SARS-CoV-2-infection and therefore identified as responding to or reactive to SARS-CoV-2. There is no verification that these expanding or contracting clonotypes have TCR specificity for SARS-CoV-2. One alternative possibility is that some, maybe even many, of these expanding or contracting clonotypes are bystander-activated T cells with TCRs that are not specific for SARS-CoV-2. Similarly, the clonotypes that were identified as contracting or expanding post-SARS-CoV-2 infection and also detected in the memory pool prior to SARS-CoV-2 infection may not be cross-reactive (i.e. specificity for another infection + SARS-CoV-2), as suggested by the authors, but rather non-SARS-CoV-2-specific bystander-activated memory T cells.</p><p>While the dynamics of the T cell populations following SARS-CoV-2 infection may be informative regardless of the mode of activation of the T cells (i.e. TCR-mediated vs. bystander activated), the reported TCR clonotype motifs are only informative if these TCRs have SARS-CoV-2 specificity.</p><p>2) Another concern is the substantial variation between the various approaches used to identify the contracting and expanding clonotypes post-infection that are associated with COVID-19 infection. The manuscript text states that the EdgeR and NoiseET approaches for identifying expanding and contracting clonotypes yielded similar results. Figure 1—figure supplement 4A, D suggest that the two approaches yield similar trajectories for the identified expanding and contracting clonotype subsets (i.e. fraction of reactive clonotypes). However, the Venn diagrams in Figure 1—figure supplement 4B, C, E, F show that the two approaches are, in some cases, identifying substantially different subsets of expanding or contracting clonotypes. For example, for Donor M in Figure 1—figure supplement 4F, of the 1044 expanded clonotypes identified by NoiseET, only 478 were also identified by EdgeR.</p><p>The text also states that the contracting and expanding clonotypes identified using EdgeR largely overlap/correspond to the clusters 2 and 3 of clonal trajectories yielded using PCA (Figure 1B-E) but no quantitative evidence is provided to support this. Venn diagrams, similar to those in Figure 1—figure supplement 4, could be provided that compare the expanding and contracting clonotypes identified using the three different approaches (i.e. EdgeR, NoiseET, and PCA) as applied to TCRα as well as TCRβ clonotypes.</p><p>While these differences between methods may not have significant consequences for some of the reported results (eg. temporal clonal trajectories), these differences raise concerns about the results that depend on specific clonotype sequences (eg. Figure 2D-G, Figure 3—figure supplement 2 and Figure S5D-G that report amino acid motifs for contracting and expanding clonotypes).</p><p><italic>Reviewer #2:</italic></p><p>This manuscript describes a longitudinal study of TCR repertoires in two individuals with mild COVID-19. TCRα and β repertoires at 4 time points post-infection are used to identify T cell clonotypes likely responding to COVID-19. These responding clones fall into two groups, a set of monotonically contracting clones and a set of clones whose frequencies peak (at day ~37) and then contract. Sequencing of memory populations at two time points and availability of TCR repertoire data from both individuals prior to infection allow the authors to map clonotypes to memory phenotypes and to identify a handful of responding clones that existed in the memory compartment prior to infection. Clusters of sequence-similar clonotypes are identified that suggest focused responses to immunodominant epitopes. This is a succinct and timely study and I have no major concerns, just a few questions/suggestions/typos detailed below.</p><p>How unexpected is the TCR clustering evident in Figure 2D-G? For example if the same number of equally high Pgen sequences were selected at random? I wonder whether the authors could run ALICE on just the responding clones (not the full dataset) to assess which neighborhoods are very unlikely to occur by chance.</p><p>Could the &quot;computational chain pairing&quot; method of Minervina et al. be applied to this data? If only to try to connect some of the sequence motifs between the α and β chains?</p><p><italic>Reviewer #3:</italic></p><p>This is a case report analysing TCR repertoire on two individuals with suspected COVID-19 infection. The report shows that a set of TCR sequences expands between days 15 and day 30/37 and another set contract. The amount of expansion/contraction is not clearly shown. Most of these sequences are found in the memory phenotype. A few (especially CD4) are found before immunisation. As the authors point out, the evidence that the TCRs recognise COVID-19 is purely circumstantial. Even if they do, I do not see that this study contributes significantly to understanding either the protective or the pathological immune response to COVID-19.</p><p>1) The Abstract is full of unsubstantiated claims. For example &quot;T cell response is a critical part of both individual and herd immunity to SARS-CoV-2 and the eﬃcacy of developed vaccines. &quot; Or &quot;In both donors we identiﬁed SARS-CoV-2-responding CD4<sup>+</sup> and CD8<sup>+</sup> T cell clones. We describe characteristic motifs in TCR sequences of COVID- 19-reactive clones, suggesting the existence of immunodominant epitopes.&quot; The authors do not identify COVID-19 responding clones; nor do they show any evidence that there are immunodominant epitopes.</p><p>2) Figure 1 What does &quot;normalized trajectory of TCR clones in each cluster&quot; mean ? It would be interesting to see the magnitude of the responses. Similarly, I don't really understand the y axis in panels d and e.</p><p>3) Figure 3. I don't understand panels a and b. Is this the proportion of contracting TCR sequences which are memory phenotype? If so, what are the rest ? Or are they simply not captured. The figure legend is obscure.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.63502.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><p>[Editors’ note: the authors resubmitted a revised version of the paper for consideration. What follows is the authors’ response to the first round of review.]</p><disp-quote content-type="editor-comment"><p>While we found the questions raised in this study interesting, we concluded that the manuscript would not be suitable for eLife without substantially more evidence that the clonotypes have TCR specificity for SARS-CoV-2. The individual reviews are appended below.</p></disp-quote><p>In this resubmission, we now provide such validation using three different approaches:</p><p>1) For the HLA-A02 positive donor M, we have acquired TCRbeta and TCRalpha sequences of TCRs binding a HLA-A02 tetramer loaded with a known SARS-CoV-2 peptide. We show that TCRs identified in this assay are independently found in our longitudinal analysis (see Figure 3A in the manuscript).</p><p>2) Additionally to our data, a large dataset of SARS-CoV-2 specific TCRs from SARSCoV-2 peptide stimulation experiments of CD8<sup>+</sup> T cells became available just recently (Snyder et al., 2020, medarxiv). We used this large set of TCR-peptide pairs to further map the specificities of COVID-19-associated TCRs identified by our longitudinal approach. Importantly, the results from this computational mapping agree well with the results we have from analysing HLA-A02 tetramer-specific clones (see Figure 3C in the manuscript). This new analysis also allows us to estimate the fraction of expanding CD8<sup>+</sup> T cells corresponding to TCRs specific for certain SARS-CoV-2 peptides in vivo.</p><p>3) Finally, to validate CD4<sup>+</sup> clonotypes (points 1 and 2 above only concerned CD8<sup>+</sup> cells), we used a large dataset of bulk TCRbeta repertoires from 1414 COVID-19 patients reported in the same study (Snyder et al., 2020). We show that the CD4<sup>+</sup> motifs we report are significantly expanded in COVID-19 patients in comparison to healthy controls (see Figure 4C,D in the manuscript). Moreover, we show that these CD4<sup>+</sup> motifs are in fact present in the majority of COVID-19 patients with matching HLA-context.</p><p>Another point raised by the reviewers was a lack of diagnostic potential of our method. We now show that the motifs identified from the longitudinal analysis are able to identify COVID positive patients.</p><p>In this revision we have also added a new timepoint at 3 months for each donor (both bulk and memory repertoires). The analysis of this timepoint provides additional information about the decay of COVID-19 associated T cell clones and their transition to long-lived memory subpopulations on a larger time scale.</p><disp-quote content-type="editor-comment"><p>Reviewer #1:</p><p>This work investigates the T cell receptor (TCR) repertoires of 2 individuals diagnosed with mild COVID-19 infection. The authors use high-throughput sequencing of 2 biological replicate samples obtained at each of multiple pre-infection and post-infection timepoints to identify TCRalpha and TCRbeta clonotypes that contract or expand post-infection and to investigate potential reactivation of pre-existing memory cells. This is a potentially interesting work that may provide novel insights into T cell responses to SARS-CoV-2. However, some of the specific details of the various analyses reported are not clear and I have several major concerns about the reported work.</p><p>1) The primary concern is the TCR specificity of the clonotypes that were determined to be contracting or expanding post-SARS-CoV-2-infection and therefore identified as responding to or reactive to SARS-CoV-2. There is no verification that these expanding or contracting clonotypes have TCR specificity for SARS-CoV-2. One alternative possibility is that some, maybe even many, of these expanding or contracting clonotypes are bystander-activated T cells with TCRs that are not specific for SARS-CoV-2. Similarly, the clonotypes that were identified as contracting or expanding post-SARS-CoV-2 infection and also detected in the memory pool prior to SARS-CoV-2 infection may not be cross-reactive (i.e. specificity for another infection + SARS-CoV-2), as suggested by the authors, but rather non-SARS-CoV-2-specific bystander-activated memory T cells.</p><p>While the dynamics of the T cell populations following SARS-CoV-2 infection may be informative regardless of the mode of activation of the T cells (i.e. TCR-mediated vs. bystander activated), the reported TCR clonotype motifs are only informative if these TCRs have SARS-CoV-2 specificity.</p></disp-quote><p>We thank the reviewer for the valuable comments. We agree that the lack of evidence of SARS-CoV-2 specificity of identified responding clonotypes was the main limitation of the previous version of the manuscript. In the revised version we provide both experimental and computational proof of the SARS-CoV-2 specificity of reported clonotypes. Donor M from the current study also participated in the study by Shomuradova et al. 2020 (as donor p1434), where T cells were sorted using a HLA-A02 tetramer loaded with a SARS-CoV-2 epitope from the spike protein. Sequences of TCRs specific for this SARS-CoV-2 epitope (YLQPRTFLL) were deposited to VDJdb after we shared our original preprint. We now use these sequences to prove that our approach is capable of identifying clonotypes specific to a certain SARS-CoV-2 epitope by clonal dynamics only, see Figure 3A. We show that a) tetramer-specific TCRs show temporal dynamics corresponding to the contracting clones’ group (monotonically decreasing in frequency after day 15 post-infection). b) Our approach identifies almost all tetramerspecific TCRs which are abundant on day 15. c) some groups of highly similar TCR sequences of contracting clones in TCRbeta and TCRalpha repertoire correspond to tetramer-specific clones.</p><p>We next compared our CD8<sup>+</sup> TCRbeta sequences with a recently published large set of TCRbetas from T cells stimulated with SARS-CoV-2 peptide pools (MIRA assay from Snyder et al., 2020, medarxiv). This allowed us to map specificities of our TCRbeta sequences to certain peptides/or pools of overlapping peptides from the MIRA assay. Importantly, this procedure correctly mapped the specificity of TCRbetas from tetramerspecific clones described above. TCR specific for one of MIRA epitopes (NQKLIANQF) were found in the pre-existing memory of donor M. Interestingly this epitope is just one mismatch away from the homologous peptide (NQKLIAN<bold>A</bold>F) of common cold betacoronaviruses, suggesting potential cross-reactivity between these two epitopes.</p><p>Finally, we prove SARS-CoV-2 association of discovered CD4<sup>+</sup> TCRbeta contracting motifs in both donors using a large cohort of COVID-19 patients from ref. Snyder et al., 2020. We show that occurrence of TCRbetas from the largest sequence similarity groups of both donors is predictive of COVID-19 positivity in donors with matching HLA-context.</p><p>1) New Figure 3A shows longitudinal tracking of A*02:01-YLQPRTFLL tetramer clones (Figure 3—figure supplement 1 for TCRalpha).</p><p>2) Occurence of tetramer clones in clusters of similar contracted TCRbetas and TCRalpha is shown on Figure 3B and c respectively.</p><p>3) Mapping of clusters of the similar CD8 TCRbetas to SARS-CoV-2 specific peptides from MIRA experiment is shown on Figure 3C as shaded circles.</p><p>4) Occurrence of main CD4<sup>+</sup> motifs from contracting clones of both donors in large cohorts of COVID-19 patients and pre-pandemic controls is shown on Figure 4C,D.</p><p>5) Separate columns in Supplementary file 3 shows if clones were detected in the tetramer enrichment experiment from Shomuradova et al., as well as specificity for peptide/peptide pool obtained by comparison with MIRA database.</p><p>6) Both Results and Materials and methods sections are updated to describe new results.</p><p>7) We note that none of these methods proved SARS-CoV-2 specificity of clones with a peak on day 37 (either because they are not specific for SARS-CoV-2, or because our validation methods are more suitable for CD8 clones). We discuss this issue in the Discussion.</p><disp-quote content-type="editor-comment"><p>2) Another concern is the substantial variation between the various approaches used to identify the contracting and expanding clonotypes post-infection that are associated with COVID-19 infection. The manuscript text states that the EdgeR and NoiseET approaches for identifying expanding and contracting clonotypes yielded similar results. Figure 1—figure supplement 4A, D suggest that the two approaches yield similar trajectories for the identified expanding and contracting clonotype subsets (i.e. fraction of reactive clonotypes). However, the Venn diagrams in Figure 1—figure supplement 4B, C, E, F show that the two approaches are, in some cases, identifying substantially different subsets of expanding or contracting clonotypes. For example, for Donor M in Figure 1—figure supplement 4F, of the 1044 expanded clonotypes identified by NoiseET, only 478 were also identified by EdgeR.</p><p>The text also states that the contracting and expanding clonotypes identified using EdgeR largely overlap/correspond to the clusters 2 and 3 of clonal trajectories yielded using PCA (Figure 1B-E) but no quantitative evidence is provided to support this. Venn diagrams, similar to those in Figure 1—figure supplement 4, could be provided that compare the expanding and contracting clonotypes identified using the three different approaches (i.e. EdgeR, NoiseET, and PCA) as applied to TCRα as well as TCRβ clonotypes.</p><p>While these differences between methods may not have significant consequences for some of the reported results (eg. temporal clonal trajectories), these differences raise concerns about the results that depend on specific clonotype sequences (eg. Figure 2D-G, Figure 3—figure supplement 2 and Figure S5 D-G that report amino acid motifs for contracting and expanding clonotypes).</p></disp-quote><p>To ensure that all of our results are reproducible with both the NOISET and edgeR approaches, we redid all the analysis and now call a clonotype “contracting” or “expanded” if it was called significant by both approaches simultaneously. Hence we show that active clonal dynamics, participation of the pre-existing memory in the response and SARSCoV-2 TCR sequence motifs we report in our initial preprint are successfully captured by both edgeR and NoisET noise models.</p><p>All figures and values in the manuscript are updated with significantly contracting and expanding clonotype groups identified with both models.</p><p>We used PCA as an exploratory data analysis technique to identify general patterns in clonotype dynamics and inform the selection of timepoints for more precise analysis with edgeR/NoisET. We do not use PCA to identify significantly contracted/expanded clones, as PCA does not take noise into account.</p><p>The overlap between clusters identified by clustering of the principal components and significant clonotypes called by both edgeR and NoisET simultaneously is now shown on Figure 1—figure supplement 5.</p><p>We also added different shapes in Figure 1BC and Figure 1—figure supplement 3A-B to indicate clonotypes called as expanding/contracting by both edgeR and NoisET.</p><disp-quote content-type="editor-comment"><p>Reviewer #2:</p><p>This manuscript describes a longitudinal study of TCR repertoires in two individuals with mild COVID-19. TCRα and β repertoires at 4 time points post-infection are used to identify T cell clonotypes likely responding to COVID-19. These responding clones fall into two groups, a set of monotonically contracting clones and a set of clones whose frequencies peak (at day ~37) and then contract. Sequencing of memory populations at two time points and availability of TCR repertoire data from both individuals prior to infection allow the authors to map clonotypes to memory phenotypes and to identify a handful of responding clones that existed in the memory compartment prior to infection. Clusters of sequence-similar clonotypes are identified that suggest focused responses to immunodominant epitopes. This is a succinct and timely study and I have no major concerns, just a few questions/suggestions/typos detailed below.</p><p>How unexpected is the TCR clustering evident in Figure 2D-G? For example if the same number of equally high Pgen sequences were selected at random? I wonder whether the authors could run ALICE on just the responding clones (not the full dataset) to assess which neighborhoods are very unlikely to occur by chance.</p></disp-quote><p>We show that clustering events are indeed unlikely to occur by chance. This can be assessed by creating a random sample of sequences from the repertoire of the same size as the responding subset, and by comparing the average number of edges in their similarity networks. That number is significantly lower in the random subset than in the responding subset (as expected, with exception of expanding CD8<sup>+</sup> clones group, there is no strong motif there).</p><p>We added new Figure 3D and Figure 4—figure supplement 1A showing the distribution of the number of edges expected under a random sampling assumption.</p><disp-quote content-type="editor-comment"><p>Could the &quot;computational chain pairing&quot; method of Minervina et al. be applied to this data? If only to try to connect some of the sequence motifs between the α and β chains?</p></disp-quote><p>We thank the reviewer for this suggestion. We applied a pairing method from Minervina et al., and found that most clusters do not show consistent pairing with each other. However, we identified two cases in CD8<sup>+</sup> contracting clones with repeated cluster-to cluster pairings.</p><p>We have added this information in the Materials and methods. The sequence of the predicted α chain for each TCRbeta clone is given in Supplementary file 3 and Supplementary file 5.</p><disp-quote content-type="editor-comment"><p>Reviewer #3:</p><p>This is a case report analysing TCR repertoire on two individuals with suspected COVID-19 infection. The report shows that a set of TCR sequences expands between days 15 and day 30/37 and another set contract. The amount of expansion/contraction is not clearly shown. Most of these sequences are found in the memory phenotype. A few (especially CD4) are found before immunisation. As the authors point out, the evidence that the TCRs recognise COVID-19 is purely circumstantial. Even if they do, I do not see that this study contributes significantly to understanding either the protective or the pathological immune response to COVID-19.</p><p>1) The Abstract is full of unsubstantiated claims. For example &quot;T cell response is a critical part of both individual and herd immunity to SARS-CoV-2 and the eﬃcacy of developed vaccines. &quot; Or &quot;In both donors we identiﬁed SARS-CoV-2-responding CD4<sup>+</sup> and CD8<sup>+</sup> T cell clones. We describe characteristic motifs in TCR sequences of COVID- 19-reactive clones, suggesting the existence of immunodominant epitopes.&quot; The authors do not identify COVID-19 responding clones; nor do they show any evidence that there are immunodominant epitopes.</p></disp-quote><p>We agree that evidence for these claims was suggestive in the initial preprint. However we believe we now provide strong evidence for these points in the revised version:</p><p>1) We provide evidence that clones identified by our longitudinal analysis are indeed COVID-19 specific with 3 different methods: by the sequencing of TCRbeta and TCRalpha of T cell clones stained with HLA*A02-tetramers loaded with YLQPRTFLL (peptide from SARS-CoV-2 spike, see Figure 3A); by matching of TCRbeta sequences to a large recently published dataset of SARS-CoV-2 reactive CD8<sup>+</sup> T cells (MIRA peptide assay, Snyder et al., 2020, see Figure 3C); and by showing preferential occurrence of both CD8 and CD4 T cell motifs in a large TCRbeta dataset of 1414 COVID-19 patients (Snyder et al., 2020), Figures 4CD.</p><p>2) In the original preprint we showed that T cell clones with active dynamics after COVID-19 frequently feature highly similar TCRbeta/TCRalpha chains. It was previously shown by multiple groups that similar TCR sequences frequently recognise the same epitope. We hypothesized that clusters of highly similar TCRs, corresponding to the large fraction of expanding cells, recognise certain immunodominant epitopes.</p><p>By sequencing TCRs from tetramer-binding sorted cells, and by searching for TCRbeta clones in databases of epitope-specific TCRs, we were able to confirm this suggestion. The new Figure 3E shows the fraction of the CD8<sup>+</sup> response mapped to certain peptides, showing that the CD8<sup>+</sup> T cells responding to the spike-derived HLA-B*15:01 restricted NQKLIANQF epitope corresponds to 21% of CD8<sup>+</sup> response at its peak. Another prominent epitope is HLA-A*02:01-YLQPRTFLL, which corresponded to 4% of CD8<sup>+</sup> response at the peak. The occurrence of the described CD4 motifs in a substantial part of HLA-matched COVID-19 patients from Snyder et al., 2020 also points towards the existence of immunodominant CD4 epitopes in the SARS-CoV-2 genome, which elicit a response in the majority of COVID-19 patients with matching HLA-context.</p><p>1) We modified the Abstract and reformulated the claims pointed out by the reviewer to be more specific.</p><p>2) We added additional analyses proving the COVID-19 specificity of the TCRs we identified and mapping them to certain epitopes:</p><p>a) New Figure 3A shows longitudinal tracking of A*02:01-YLQPRTFLL tetramer specific clones (Figure 3—figure supplement 1 for TCRalpha).</p><p>b) The occurrence of tetramer-positive clones in clusters of similar contracted TCRalpha and TCRbeta clonotypes is shown in Figure 3B and C.</p><p>c) The mapping of TCRbeta clusters to SARS-CoV-2 specific peptides from the MIRA experiment is shown in Figure 3C (shaded circles).</p><p>d) The occurrence of the main CD4<sup>+</sup> motifs of contracting clones from both donors in large cohorts of COVID-19 patients and the pre-pandemic control cohort is shown in Figure 4C, D.</p><p>e) Separate columns in Supplementary file 3 report if clones were detected in the tetramer enrichment experiment from Shomuradova et al., as well as the specificity for peptides from the MIRA database.</p><p>f) Both the Results and Materials and methods sections are updated to describe the new analyses.</p><disp-quote content-type="editor-comment"><p>2) Figure 1 What does &quot;normalized trajectory of TCR clones in each cluster&quot; mean ? It would be interesting to see the magnitude of the responses. Similarly, I don't really understand the y axis in panels d and e.</p></disp-quote><p>1) We reformulated and expanded Figure 1’s caption to make it clear that clonal frequencies are normalized by the maximum value for each clone in Figure 1B-C, and that Figure 1B-C’s left panels show the average of such normalized frequencies within each cluster (and thus show the dynamical pattern of an average clone in that cluster).</p><p>2) We now discuss the magnitude of the responses in the text.</p><p>3) We reformulated the Figure 1D-E caption to explain the y-axis more clearly: it is the sum of the frequencies of all clonotypes detected as “contracting” (D) and “expanding” (E).</p><disp-quote content-type="editor-comment"><p>3) Figure 3. I don't understand panels a and b. Is this the proportion of contracting TCR sequences which are memory phenotype? If so, what are the rest ? Or are they simply not captured. The figure legend is obscure.</p></disp-quote><p>Yes, this is correct. These data are now shown in Figure 2, and we have expanded its caption to explain it more clearly. We profile PBMC repertoires more deeply than repertoires of FACS sorted memory cells, and thus indeed low-abundant responding clones are captured in PBMC, but not in memory subpopulations. We have added a discussion of this sampling issue in the text.</p></body></sub-article></article>